0

1

The Southeast BIO (SEBIO) Investor & Partnering Forum is the Southeast region’s premier life sciences and medical technology conference, connecting emerging companies with potential investors and partners in a forum that provides meaningful networking opportunities. Celebrating its 20th anniversary, this event has built a loyal following of thought leaders and investors from across the country. We expect another sensational event in 2018. We anticipate about 300 biotech and medtech investors, corporate executives, university representatives, entrepreneurs, and service providers will attend this year. To date, the more than 200 later stage and 165 early stage companies that participated in previous SEBIO Investor & Partnering Forums have raised more than $3.5 billion in public and private funding. These numbers speak to the quality of our presenting companies.

Officers: Chair: Todd Sherer, PhD, Emory University, Office of Technology Transfer Vice-Chair: Tina McKeon, Kilpatrick Townsend & Stockton, LLP Treasurer: Mark Baxter, Ernst & Young Secretary: Tom Callaway, MD, Life Science Partner Ex Officio: Sue Washer, AGTC

Executive Committee: Brian Adams, PhD, Arbor Pharmaceuticals Mark Baxter, Ernst & Young Tom Callaway, MD, Life Science Partner, Inc. Becky Kaufman, King & Spalding LLP Tina McKeon, Kilpatrick Townsend & Stockton, LLP Jennifer Sherer, PhD, Georgia State University Entrepreneurship and Innovation Institute Todd Sherer, PhD, Emory University, Office of Technology Transfer Sue Washer, AGTC

SEBIO Office: David Day, Executive Director Gabrielle Morrow, Administrative Assistant

Directors: Russell Allen, Georgia Research Alliance William Brooke, Harbert Ventures Partners Gerry Brunk, Lumira Capital Nancy Bryan, BioFlorida Joe Cook, III, Mountain Group Partners Todd Creech, HeathQuest Capital Machelle Dunavan-Shields, Butler Snow Greg Duncan, Celtaxsys, Inc. Ken Eheman, Wyrick Robbins Tom Fagley, Hughes Pittman & Gupton, LLP Jeff Gallagher, Virginia Biotechnology Association H. Lee Herron, DVM, Georgia Research Alliance Frank Hunt, PNP Therapeutics, Inc. Sam Konduros, SCBIO Andrew Krouse, Cavion, LLC Sharon Krueger, University of Virginia, Office of the VP for Research

Scott McCarty, Silicon Valley Bank Bibhash Mukhopadhyay, PhD, New Enterprise Associates Kathy Nugent, PhD, UAB Institute for Innovation and Entrepreneurship Jim O’Connell, University of Florida UF Innovate Dan O’Korn, Hutchison Law Group, PLLC David Pierson, Syngenta Crop Protection Robin Rasor, Duke University, Office of Licensing & Ventures James Rosen, Artizan, Biosciences, Inc. David Stern, Contego Medical Ken Tindall, PhD, North Carolina Biotechnology Center Evan Travis, Square 1 Bank Abby Trotter, Life Science Tennessee Miriam Wilson, Council for Entrepreneurial Development (CED) Ford Worthy, Pappas Capital Karen Zederej, AxoGen, Inc.

2

Table of Contents

Welcome Letters ……………………………………………………………………………………….. 3

Steering Committee ……………………………………………………………………………………. 5

Subcommittees …………………………………………………………………………………………. 6

General Information ……………………………………………………………………………………. 7

Conference Floor Plan . .………………………………………………………………………………. 8

Agenda …………………….……………………………………………………………………………... 9

Main Stage Company Profiles .………………………………………………………………………. 11

Early Stage Company Profiles .……………………………………………………………………… 21

Speaker Biographies ..………………………………………………………………………………… 52

2018 SEBIO Awards . ..………………………………………………………………………………… 62

Sponsors ………………………………………………………………………………………………… 64

3

Welcome

November 13, 2018

As Chair of SEBIO, I would like to welcome you to the 2018 Southeast BIO Investor & Partnering Forum in Atlanta, GA! Under the watchful eye of our Forum Chairs, Brian Adams of Arbor Pharmaceuticals and Jennifer Sherer of Georgia State University, we have a fantastic conference planned for you here at Loews Hotel Atlanta. As the region’s premier investor conference, we are very proud to showcase the bustling life science industry that thrives here in the Southeast. Our Program Chair, Becky Kaufman of King and Spalding led the team that pulled together a compelling agenda with several notable speakers. Our keynote speaker this year is Jeff Arnold, Chairman and CEO, Sharecare, a health and wellness engagement platform that provides users with personal health tools and co-founded with Dr. Mehmet Oz. Arnold also founded WebMD, a health care company that provides consumers, health institutions, and physicians with medical information through the Internet. The rest of the packed agenda includes panels on Early Stage Investing, Corporate VCs, Neuroscience and the Future of the Medical Device Industry featuring one of the leading investors in the medical device industry, Justin Klein of NEA. There are also Main Stage company presentations and the Early Stage Shootout. As always, we have several networking opportunities planned to facilitate “collisions” within our life science community. Please plan to join us for the Kick-Off Reception on Tuesday night as well as the Gala Reception on Wednesday night. There will be many other opportunities to network as well. It was my pleasure to serve as your 2017 & 2018 Chair of SEBIO. We have a very successful Board of Directors who are guided through the accomplished leadership of David Day, SEBIO Executive Director. Please don’t hesitate to approach any of us with interest, ideas or innovative solutions that will further enrich life sciences in the Southeast. In closing, I want to thank our generous sponsors for making the 2018 SEBIO Forum possible as well as our dedicated Steering Committee (Brian Adams, Jennifer Sherer, Kornelius Bankston, Becky Kaufman, Doug Gooding, Joe Cook, III, Evan Travis, Peter Young, Scott McCarty, David Weingarten, Tom Callaway, Tina McKeon, Mark Long and Evan McClure). Don’t forget to mark your calendars for SEBIO 2019 in Miami, FL! Sincerely, Todd Sherer SEBIO Board Chair Emory University

4

Welcome

November 13, 2018

Welcome to the 20th Annual Southeast BIO Investor & Partnering Forum. The SEBIO Investor & Partnering Forum is one of the nation’s premier life sciences conferences, connecting investors and partners with the Southeast’s most promising companies. We are proud to note that the companies presenting at the past 19 Investor & Partnering Forums have raised more than $3.5 billion in private and public funding since their presentations, and a number of other presenting companies have had successful exits.

We know that you will make the most of the Forum, networking with your colleagues and learning more about the companies. The Forum is made possible by many generous sponsors. Please take time to thank each of our sponsors for their support of the conference and to learn more about the sponsoring companies by touring their exhibits.

The Forum is featuring some fantastic speakers in this year’s compacted agenda, from our keynote speaker, serial entrepreneur Jeff Arnold, to panels on early stage investing and corporate venture capital. We also have panel discussions focused on neuroscience and the future of the medical device industry. As always, our main focus is the companies: both our Main Stage company presentations and the Early Stage Shootout.

We added “Partnering” to our title a few years ago, and we believe that the conference will provide you with ample partnering opportunities. These partnering opportunities are enhanced, as in past years, with one-on-one meetings through the SEBIO Connect system. This activity is software driven and free for all Forum registrants. Be sure to download the SEBIO mobile app to your phone or tablet to view agendas, floor plans, speaker bios and sponsor info and to manage your SEBIO Connect meetings.

We extend our sincere appreciation to our Steering Committee and thank every one of the many committee members for the time and effort taken to make this Forum so successful. Please note the contributions of these individuals whose names are listed in the pages that follow. We greatly appreciate their support and acknowledge that the Forum could not happen without them.

We trust that the Forum will introduce you to some of the region’s most promising young companies and new business partners and that you will enjoy the resources and activities that Atlanta has to offer. We are pleased to have you here in Georgia, and we hope you will continue to make the SEBIO Investor & Partnering Forum an annual tradition on your calendar of events. We look forward to seeing you in Miami next year.

Brian Adams and Jennifer Sherer Southeast BIO Investor & Partnering Forum Co-Chairs VP, Business Development, Arbor Pharmaceuticals Director, Entrepreneurship & Innovation Institute, Georgia State University

5

2018 SEBIO Investor & Partnering Forum Steering Committee

Conference Co-Chairs Brian Adams, PhD, Arbor Pharmaceuticals Jennifer Sherer, PhD, Georgia State University Entrepreneurship and Innovation Institute

SEBIO Chair Todd Sherer, PhD, Emory University, Office of Technology Transfer

SEBIO Vice-Chair Tina McKeon, Kilpatrick Townsend & Stockton, LLP

Program Chair Becky Kaufman, King & Spalding

Awards Chair Evan McClure, Life Science Partner

Company Selection Chair Peter Young, Pappas Capital

Sponsorship Chair David L. Day, SEBIO

Early Stage Chair Doug Gooding, Knowles Intellectual Property Strategies

Marketing Co-Chairs Becky Kaufman, King & Spalding Kornelius Bankston, Color Genomics

Company Recruitment Co-Chairs Joe Cook, III, Mountain Group Partners Evan Travis, Square 1 Bank Mark Long, University of Florida Scot McCarty, Silicon Valley Bank

Corporate Partnering Chair Brian Adams, PhD, Arbor Pharmaceuticals

Networking Chair David Weingarten, PhD, Finnegan

Golf Co-Chairs Evan Travis, Square 1 Bank Kelley Matthews, Sun Trust Private Wealth Management

Steering Committee Members Dan O’Korn, Hutchison Kathy Nugent, University of Alabama Birmingham Robin Rasor, Duke University, Office of Licensing & Ventures Tom Callaway, MD, Life Science Partner

Meeting Organizer Tim Barrett, CMP, Destination South Meetings + Events

6

2018 SEBIO Investor & Partnering Forum Subcommittees

Early Stage Mentors Brian Adams, PhD, Arbor Pharmaceuticals Brent Bellows, PhD, Knowles Intellectual Property Strategies Justin Burns, PhD, Emory University Office of Technology Transfer Robert Creeden, UVa LVG Seed Fund Shana Cyr, PhD, Finnegan Christine Dixon, Thiesing, SCRA Vivian Doelling, North Carolina Biotechnology Center Doug Gooding, Knowles Intellectual Property Strategies H. Lee Herron, Georgia Research Alliance Becky Kaufman, King & Spalding Kurt Jacobus, PhD, GRA Venture Fund Mankit Law, PhD, Pappas Capital Tina McKeon, Kilpatrick Townsend & Stockton, LLP Kathy Meserve, North Carolina Biotechnology Center Jacob Moore, PhD, Womble Bond Dickinson (US) LLP Ryan O’Quinn, PhD, Finnegan Sumitra Pati, PhD, UNC Eshelman Institute for Innovation Sanjay Razdan, Arbor Pharmaceuticals Connor Seabrook, Georgia Research Alliance Kyp Srinakis, Epidarex Capital Peter Young, Pappas Capital

Recruitment Committee Vivian Doelling, North Carolina Biotechnology Center Erin Ford SCBIO Jeff Gallagher, Virginia BIO Doug Gooding, Knowles Intellectual Property Strategies Laura Gunter, NCBIO H. Lee Herron, DVM, Georgia Research

Alliance Sam Konduros, SCBIO Sharon Krueger, University of Virginia, Office of the VP for Research Mark Long, University of Florida Sam Patrick, SCBIO Amy Sturdivant, HudsonAlpha Amy Trotter, Life Sciences Tennessee Peter Young, Pappas Capital

Selection Committee Michael Ackerman, Arrivo Bioventures Anurag Agarwal, Osage University Partners Peter Alff, Kairos Ventures Gerry Brunk, Lumira Sarah Caley, bioventus Joe Cook, III, Mountain Group Partners Robert Creeden, UVA LVG Seed Fund Vivian Doelling, North Carolina Biotechnology Center Omar Flores, Mountain Group Partners Doug Gooding, Knowles Intellectual Property Strategies H. Lee Herron, DVM, Georgia Research Alliance Mankit Law, PhD, Pappas Capital George Lasezky Scott McCarty, Silicon Valley Bank Sanjeev Munshi, Merck Stephen Nagler, MedProAngels Gladys Nunez, Amgen Ventures Jay Rosanelli, Powder Gate Capital Austin Schwartz, Florida State University Ben Scruggs, Hatteras Venture Partners Kyp Sirinakis, Epidarex Capital Evan Travis, Square 1 Bank Michal White, Founders Investors Chong Xu, fPrime Capital

7

General Information

Registration and Information Desk The Southeast BIO Investor & Partnering Forum registration and information desk will be open on Tuesday, November 13 from 9:00am to 7:00pm and Wednesday, November 14 from 7:00am to 5:00pm in the Ellington Ballroom Foyer. This desk will also serve as a message center where all changes to the agenda and other important notices will be posted.

SEBIO Mobile App Please download the SEBIO Connect mobile app from the Apple or Play Store at no cost to schedule one-on-one meetings, get access to agendas, floor plans, company information and other vital conference details. A personalized invitation is sent to all attendees. If you have not received yours, please stop by the registration and information desk.

Name Badges Attendees and guests are required to wear their name badges at all SEBIO functions. Please assist conference personnel and other participants by displaying your badge in a prominent place. Entry to an SEBIO function may be denied to anyone not wearing a name badge.

Business Center The fully equipped Loews Atlanta Business Center is conveniently located on the ballroom level. This center is accessible 24 hours a day and offers services including computer access and printing.

Yoga New this year is the opportunity to start your morning with a yoga session in the hotel’s Exhale Spa. Please RSVP at the registration and information desk if you did not sign up during registration.

Cellular Phones

Please remember to turn OFF your cell phones while attending sessions.

8

Conference Floor Plan

Loews Atlanta

Early Stage Mentoring Ardmore Boardroom Chastain Pittman

Kick-Off Reception Overlook East

General Sessions & Meals Ellington Ballroom ABCD

Medical Device Panel Ellington Ballroom EF

Gala Reception The Terrace

Biotech/Pharma Panel Overlook West

9

Tuesday, November 13

8:00 AM – 3:00 PM

Investor Golf sponsored by SunTrust Private Wealth & Square 1 Bank (invitation only)

East Lake Country Club

9:00 AM – 7:00 PM

Registration

Ellington Ballroom Pre-function

9:00 AM – 6:00 PM SEBIO Connect sponsored by Finnegan See SEBIO Connect app

2:30 PM – 5:00 PM

Early Stage Mentoring

Team A: Ardmore Team B: Boardroom Team C: Chastain Team D: Pittman

5:00 PM – 6:30 PM

Board of Directors Meeting + Reception (invitation only) Ravinia

5:00 PM – 8:00 PM Exhibitor Setup Ellington Ballroom Prefunction

6:30 PM – 8:00 PM Kick-Off Reception Overlook East

7:30 PM – 9:30 PM Investor Dinner sponsored by Emory University Office of Technology Transfer & South Carolina Research Authority (SCRA) (invitation Only)

The Peachtree Club

Wednesday, November 14

7:00 AM – 8:00 AM Yoga Exhale Spa Yoga Studio

7:00 AM – 5:00 PM Registration Ellington Ballroom Prefunction

8:00 AM – 6:00 PM SEBIO Connect sponsored by Finnegan See SEBIO Connect app

8:00 AM – 8:30 AM Continental and Connecting Ellington Ballroom Prefunction

8:30 AM – 9:30 AM

Early Stage Investing – And We Mean Early sponsored by Metro Atlanta Chamber

• Doug Gooding, Business Advisor and Technical Specialist, Knowles Intellectual Property Strategies

• Bob Creeden, Managing Director, UVA LVG Seed Fund & New Ventures

• Bob Crutchfield, Managing Director, BrightEdge Venture Fund

• Dennis Liotta, Ph.D., Executive Director, Emory Institute for Drug Development

• Alan Bentley, Assistant Vice Chancellor, Vanderbilt Center for Technology Transfer and Commercialization

Ellington Ballroom ABCD

9:45 AM – 10:45 AM

Corporate Venture Capital Panel sponsored by HighPoint Solutions

• Steven Hall, Ph.D., General Partner, Lilly Ventures (Moderator)

• Gladys Nunez, Principal, Amgen Ventures

• Charles Kunsch, Ph.D., Senior Director, AbbVie Ventures

• Linda Lohr, Ph.D., Senior Director, Worldwide R&D, Pfizer

Ellington Ballroom ABCD

10:45 AM – 11:00 AM Coffee and Connecting Ellington Ballroom Prefunction

10

Wednesday, November 15 (continued)

11:00 AM – 11:45 AM

Company Presentations sponsored by Brand Institute

• Concert Genetics

• Celtaxsys

• NeuroTronik Limited

Ellington Ballroom ABCD

11:45 AM – 12:15 PM Coffee and Connecting Ellington Ballroom Prefunction

12:15 PM – 1:45 PM

Awards Luncheon & Keynote sponsored by Georgia Research Alliance

• Initial Funding Award - Initial equity financing of less than $1 million

• Venture Funding Award - Equity financing of greater than $1 million

• Strategic Investment Award - Strategic investment in award company by a peer

• Strategic Acquisition Award - Material acquisition of an award company or by an award company

• Initial Public Offering Award - Initial securities offering to the public

• Keynote - Jeff Arnold, Chairman and CEO, Sharecare

• Lifetime Achievement Award

Ellington Ballroom ABCD

1:45 PM – 2:00 PM Coffee and Connecting Ellington Ballroom Prefunction

2:00 PM – 2:45 PM

Company Presentations sponsored by Brand Institute

• Spyryx Biosciences

• AKESOgen

Ellington Ballroom ABCD

2:45 PM – 3:00 PM Networking Break Ellington Ballroom Prefunction

3:00 PM – 4:00 PM

Neurosciences - 20 Years Later: A Conversation sponsored by University of Florida Innovate

• Max Wallace, J.D., Chief Executive Officer, Accelerate Brain Cancer Cure (Conversation Leader)

• T (Teo) Forcht Dagi, M.D., CEO, Boston Neurosciences

• Shawn Hingtgen, Ph.D., Founder, Falcon Therapeutics

• Owen B. Samuels, M.D., Medical Director, Emory University Division of Neurointensive Care

Overlook West

3:00 PM – 4:00 PM

The Future of the Medical Device Industry sponsored by Davis, Malm & D’Agostine, P.C.

• Scott Weiner, Partner, Pappas Capital (Moderator)

• Jed Cohen, Managing Director, Leerink

• Justin Klein, M.D., J.D., Partner, NEA

• Timothy Patrick, President, CEO and Co-Founder of Cartiva

• Peter Shagory, Executive Vice President, ConMed

Ellington Ballroom EF

4:00 PM – 5:00 PM Wine Reception sponsored by Silicon Valley Bank Ellington Ballroom Prefunction

5:00 PM – 6:00 PM

Early Stage Shootout sponsored by Wyrick Robbins

• Doug Gooding, Business Advisor and Technical Specialist, Knowles Intellectual Property Strategies (Host)

Ellington Ballroom ABCD

6:00 PM – 7:30 PM Gala Reception & Early Stage Shootout Winner Announcement sponsored by King & Spalding

The Terrace

11

AKESOgen, Inc. (Main Stage) 3155 Northwoods Place Peachtree Corners, GA 30071 Phone: (770) 542-0890 www.akesogen.com

Presenter(s) Chief Executive Officer: Robert P. Boisjoli, FCPA, FCA, CBV Mr. Boisjoli is a Fellow Chartered Accountant (FCA) and a Chartered Business Valuator (CBV) having obtained a Bachelor of Commerce and Diploma in Accounting at Concordia University. Mr. Boisjoli is also a partner at Robert Boisjoli & Associes, S.E.C. and Atwater Financial Group. From 2008 to early 2010, he was Chief Financial Officer of Topigen Pharmaceuticals Inc. until its sale in February 2010 to Pharmaxis, an Australian based biopharmaceutical company. From 2001 until 2008, Mr. Boisjoli was the Chief Financial Officer, Chief Operating Officer (2005-2008) and co-founder of Xanthus Pharmaceuticals, Inc. until its sale in June 2008 to Antisoma PLC, a UK based biopharmaceutical company. Mr. Boisjoli sits on the boards of various companies including Palos Management Inc and AICA Services Inc. He was also an investment banker with various Canadian securities' firms. Mr. Boisjoli was instrumental in setting up a mutual fund in the Quebec market and authored over 500 business valuation reports for regulatory, M&A transactions and other purposes. Chief Scientific Officer: Mark Bouzyk, Ph.D. has been AKESOgen’s Chief Scientific Officer for more than 7 years. Prior to this he held a faculty position for approximately 6 years at Emory University, Atlanta, GA where he directed and established many of the Core facilities. Prior to Emory Dr. Bouzyk spent approximately 9 years at GlaxoSmithKline where as a senior corporate executive he had transnational accountability as Director of Genetic Laboratory Sciences leading the company's high throughput genomic efforts in Europe. Dr. Bouzyk also has worked as a scientist in the UK’s leading cancer charity, Cancer Research UK as well as several years in the UK government’s Medical Research Council at the National Institute for Medical Research.

Company Profile AKESOgen is a precision health and wellness population genomics company with a unique vision - to give every individual access to their DNA in order to enhance their lives through health and wellbeing – both from a consumer genomics and clinical sequencing strategy. AKESOgen works in the new paradigm health and wellness ecosystem by generating personalized DNA profiles so people can explore uniquely personalized products developed by the innovative companies with whom we have formed partnerships. AKESOgen generates DNA data and manages data privacy so that every individual is in complete control of their own data. Our ecosystem incorporates DNA data into personalized reports for each individual across a spectrum of categories, including ancestry, fitness, weight management and health. AKESOgen is based in greater Atlanta, Georgia, and is CLIA certified and CAP-accredited. AKESOgen has a full complement of genomics and epigenetics platforms from genotyping & sequencing to methylation. AKESOgen was founded in 2010 and has approximately 45 staff and growing. It made the Inc. 500 list of fastest growing companies three years in a row. www.akesogen.com.

Product and Technology AKESOgen is ‘a new breed’ of precision genomics CRO that utilizes the latest ‘omics technologies to support its clients. These clients range from academia, pharma, biotech, government and ‘direct to consumer’ companies. AKESOgen’s technologies are scalable and high-throughput – likely the largest genomics capabilities in the state of Georgia (e.g. we have the ability to extract DNA from ~6,000 samples daily). AKESOgen has taken next generation genomics to a new level beyond well-known companies in this area such as Ancestry and 23andMe with new product lines -such as its partnership with Nutrisystem to use DNA in the Nutrisystems weight management program. AKESOgen has partners on a ‘b to b’ basis with more than 20 direct to consumer genetics companies. Other high profile projects include AKESOgen’s involvement in generating the genetic data for the US Department of Veteran’s Affairs Million Veterans Project to genotype a million US veterans – still, the largest genetics project of its kind ever performed in the world by population. Other partners with AKESOgen include Cytox which has developed an algorithm to predict a Genetic Risk Score for likelihood of late onset Alzheimer’s where assays are run in AKESOgen’s laboratories.

12

Market Potential The direct to consumer space the market and clinical sequencing market is exploding. It is forecast at $2- $7BN globally. Pharma and research partnerships are forecast at $1.5BN (Source: Genomics 2.0 UBS Report). This is also evidenced by statements from Illumina CEO Francis de Souza at JP Morgan Healthcare conference in 2018. It took both Ancestry and 23andMe 7-8 years to reach 7-8M users. In 2017 over 12M people had taken a genetic test. In 2018 approximately 30M people will have taken a genetic test. These numbers will be compounded by companies entering this space using DNA to upsell their products –and AKESOgen is well paced to be a prime leader capturing this market.

https://www.technologyreview.com/s/610233/2017-was-the-year-consumer-dna-testing-blew-up/

Management Team In addition to Robert Boisjoli and Mark Bouzyk (above): Laura Stowers, MBA: VP of Operations has more than 16 years managing hospital and medical center laboratory systems at Gwinnett hospital system prior to joining AKESOgen 18 months ago. Lauren McGoldrick, BS: VP of Project Management has directed project management at Quintiles/Q2Solutions for more than 6 years as well as similar roles at LGS for approximately 6 years before joining AKESOgen. Maria Mikkleson, MBA: VP of IT spent nearly 13 years managing global IT operations at Quintiles IMS as well as a 6-year spell at Hewlett Packard. She has been running IT at AKESOgen for more than 2 years. Brian Bunke, BS: Director of Operations has managed Technical operations at both Emory Genetics Laboratories and Eurofins for 24 years before his recent appointment at AKESOgen.

Financial Forecasts AKESOgen is entering a period of substantial growth. It is seeking $2M to $5M to provide required working capital to support $20M of revenue in 2019 and also to enable it to move into larger premises in 2020 to handle the increase volume of samples processed. AKESOgen is projecting the following Revenue and EBITDA for the next five years:

13

Celtaxsys, Inc. (Main Stage) 201 17th Street Suite 530 Atlanta, GA 30363 Phone: (470) 206-0153 www.celtaxsys.com awalsh@celtaxsys.com

Presenter Greg Duncan, MBA, President & CEO, was an EVP and President of North American Operations for Brussels based specialty pharma UCB; prior to that, he was the President of European and Emerging Market Operations. Before joining UCB, Greg spent 17 years with Pfizer where he held several U.S. and International executive appointments, including SVP of Marketing and President of Pfizer’s Latin America Operations.

Company Profile Celtaxsys, Inc., is a privately held, Atlanta based, clinical stage pharmaceutical development company focused on advancing anti-inflammatory treatments for patients with rare inflammatory diseases. In a recently completed 200 patient, double-blind, placebo controlled study, our lead medicine, once daily, oral acebilustat, demonstrated clinically meaningful improvements in pulmonary exacerbations, both reducing the frequency of pulmonary exacerbations and increasing time to next exacerbation over 48 weeks of therapy for patients with Cystic Fibrosis (CF). Acebilustat is the first novel anti-inflammatory molecule evidencing the potential to reduce frequency of pulmonary exacerbations, prolong time to first exacerbation and increase the likelihood of CF patients remaining exacerbation free, with greatest benefits observed in mild patients and/or those on CFTR modulator therapy. Celtaxsys, with continued support from the CF Foundation, has commenced preparations for executing the acebilustat Phase 3 CF clinical program in 2H 2019.

Product and Technology Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, recently announced top line results of our Phase 2 EMPIRE-CF trial evaluating oral, once daily anti-inflammatory molecule, acebilustat, for the treatment of cystic fibrosis (CF), irrespective of the causative genotype. In the 200 patient, double-blind, placebo controlled study, acebilustat demonstrated clinically meaningful improvements in pulmonary exacerbations, both reducing the frequency of pulmonary exacerbations (PEx) and increasing time to next exacerbation over 48 weeks of therapy. Full results from the trial were presented at the North American Cystic Fibrosis Conference (NACFC) held October 18-20, 2018 in Denver, Colorado. “The North American Cystic Fibrosis Conference provided an ideal opportunity for Dr. Steven Rowe and Dr. Stuart Elborn, both principal investigators for our Phase 2 trial of acebilustat, to present the comprehensive results from the trial to the CF community. These data showed that acebilustat has the potential to reduce the rate of pulmonary exacerbations in CF patients, including patients on a CFTR modulator. This is a critically important health outcome for the CF population that we expect to explore further,” said Greg Duncan, CEO of Celtaxsys. “We would like to thank Dr. Rowe and Dr. Elborn for their expert guidance throughout the trial and their participation in these presentations. We are also grateful to the patients and investigators who participated in the study.” Celtaxsys, with continued support from the CF Foundation, has commenced preparations for designing and executing the Phase 3 clinical program of acebilustat.

14

Management Team Greg Duncan, MBA, President & CEO, was most recently Executive Vice President and President of North American Operations for Brussels based specialty pharma UCB. He was responsible for providing leadership and strategic direction to all aspects of the organization’s operations in North America. Prior to that, he was the President of European and Emerging Market Operations. Before joining UCB, Greg spent 17 years with Pfizer where he held several U.S. and international executive appointments, including SVP of Marketing and President of Pfizer’s Latin America Operations. His brand and general management teams had accountability for the launches of many “blockbuster” pharmaceutical brands including Lipitor, Zoloft, Viagra, Celebrex, Aricept, Lyrica, Cimzia, Zithromax (ZPack), Diflucan, Sutent and Vimpat. Greg presently serves as an independent board director for Alliance Health and has served as a Board Director of the American Psychiatric Foundation, Biotie Therapeutics, Bio International Organization (BIO) and the Georgia Bio industry association groups. Greg holds a master’s degree in business administration from Emory University in Atlanta, GA, and a bachelor’s degree in economics from the State University of New York in Albany, NY. He and his wife Jennifer are the proud parents of three wonderful children. Sanjeev Ahuja, MD, MBA, FACP, Chief Medical Officer, has over 30 years of experience as a physician including over 14 years in the pharmaceutical/biotechnology industry. He has training and clinical practice experience in obstetrics-gynecology and internal medicine. Since joining the industry in 2000 at Lilly, he has been involved in drug development across several therapeutic areas and in all phases of clinical development. Sanjeev’s industry experience spans large pharmaceutical companies and start-ups. He helped establish the R&D joint venture for Lilly in India, managed the R&D collaborations in immunology-inflammation for Sanofi Genzyme, and till most recently was the Chief Medical Officer at On Target Laboratories. Sanjeev’s medical degree is from the Armed Forces Medical College, Pune, India. He is a Fellow of the American College of Physicians, and also has an MBA from the University of Cincinnati. Eric Springman, PhD, Chief Scientific Officer, joined Celtaxsys in 2009 from Locus Pharmaceuticals, where he held several positions of increasing responsibility including Head of Discovery and Technologies and Head of Development. At Locus, he was instrumental in building core technologies as well as discovering and developing 3 clinical candidate compounds resulting in over $50M in partnerships and $30M in venture funding. Additionally, Dr. Springman obtained over $3M in public and private grant funding for research and served as an NIH SBIR grant reviewed. In 2007, Dr. Springman was appointed by Gov. Edward Rendell to serve on the Pennsylvania Drug, Device and Cosmetics Board for which he served 4 years. Prior to Locus, Dr. Springman, served as Head of the Arthritis and Fibrosis Therapy Area at Roche Pharmaceuticals and Group Leader at Arris/Axys Pharmaceuticals. Dr. Springman received his PhD in Molecular Biophysics from Florida State University and conducted his postdoctoral studies at Vanderbilt University School of Medicine, where he was an American Lung Association Fellow and NIH NRSA Postdoctoral Fellow. He was accepted into the American Academy of Allergy, Asthma and Immunology in 1993. Angela Walsh, BS, Vice President of Finance, joined the Celtaxsys team in March 2016 from Green Circle Bio Energy, a renewable energy company based in Cottondale, Florida. As the CFO of Green Circle, she was responsible for all aspects of strategic planning and financial reporting, audit and tax oversight, cash management, financial modeling and forecasting. Angela led the due diligence process for the acquisition of the Company by Enviva Partners, LP. Post the acquisitions, Angela assisted Enviva in their preparations for their S-1 filing and subsequent IPO in May 2015. Before Green Circle, Angela worked five years for Altea Therapeutics, a start-up transdermal drug delivery company based in Atlanta, Georgia. In her role as the VP of Finance, she assisted in raising capital as well as assisted in the licensing of its technology to two pharmaceutical partners. Angela has over 25 years of experience in the accounting field and began her career with Arthur Andersen in Greensboro, North Carolina. Angela hold a BS in Accounting from Wake Forest University.

15

Concert Genetics, Inc. (Main Stage)

130 Scripps Way, Jupiter, FL 33458 800-983-8098 www.blinkbioinc.com mcardone@blinkbioinc.com

Presenter Dr. Colin Goddard Ph.D., Chairman and CEO is an investor in the company and has been part of the leadership team since the inception of BlinkBio in 2015. Dr. Goddard was formerly CEO of OSI Pharmaceuticals for 12 years, raising over $1.5 billion and overseeing the development, launch and commercialization of the lung cancer drug Tarceva through to OSI’s $4 billion acquisition by Astellas. He also Chairs the board of Mission Therapeutics and is a board member of the drug conjugate company Endocyte (NASDAQ:ECYT). Dr.Goddard obtained his PhD in cancer chemotherapy in the UK and completed post-doctoral training at the National Cancer Institute in Bethesda, MD.

Company Profile BlinkBio is a privately held anti-cancer drug discovery and development company. BlinkBio began operations in 2015, having emerged from a predecessor company to exploit internally innovated technologies in the field of drug conjugates. The company employs 9 people, 6 in R&D, and supplements its research efforts through the extensive use of contract research organizations. Our investors are a mix of individual investors and VC funds. To date the Company has invested ~$8 million in developing its technology. Our near-term objectives are focused on pre-clinical development in our lead program (where we expect to have our first drug candidate enter the clinic in 1Q2019) and securing technology and project based partnerships with pharmaceutical or other biotech companies in order to establish the breadth of our technology and to broaden our pipeline. Our longer term (three year) objective is to deliver liquidity to our investors via either an M&A transaction or an IPO.

Product and Technology Drug conjugates are complex medicines designed to deliver potent toxins to cancer cells by targeting proteins that are specifically over-expressed on the surface of cancer cells. Antibody Drug Conjugates (ADCs) dominate the field and employ an antibody to bind targeted proteins and chemical linkers that are intended to release toxins (‘payloads’) inside cancer cells. The approach has been both clinically and commercially validated, with Kadcyla and Adcetris alone combining for ~$1.4 billion in 2016 annual revenues following their launches in 2013 and 2011. While ADCs have established the potential value of this approach there is still significant opportunity for innovation. For example, ADCs can stay in the body for weeks, exposing patients to unintended off-target toxicity and the ADC molecules themselves are too big to optimally penetrate tumors.

We have designed Tunable Drug Conjugates (TDCs) based on the concept that the rapid and uniform release of toxin payloads inside tumors, coupled to the rapid systemic clearance of the parent TDC after dosing, will improve both the efficacy and safety of drug conjugates. Using small molecule or antibody fragments for targeting we anticipate better tumor penetration. We also expect that our TDCs can be cleared from the body within 24-36 hours after dosing, minimizing systemic exposure and have demonstrated this in mouse pharmacokinetic studies. Our SiLinker/payload cassette system allows rapid and tunable cleavage of selected linkers and the release of multiple and/or mixed payloads inside targeted cancer cells and within the necrotic core of tumors. This unique set of properties has been shown to be highly effective in mouse xenograft models and candidate selection is ongoing for our lead Folate Receptor alpha (FRα) targeting project for ovarian and lung cancer. Preliminary data with prototype TDCs has shown a clear dose response and also allowed us to demonstrate the performance of our payload cassettes in obtaining ‘cures’ in xenograft models after just two once-weekly doses under conditions that showed no body-weight loss in the tested mice (body weight loss is an indication of tolerability of the prototype TDC). We have filed patents to protect all elements of our technology (ligands/linkers/payloads and payload cassettes) and continue to expand this IP estate as we build out our ‘modular toolbox’ of technology assets.

16

Market Potential Anti-cancer drug conjugate therapies generated global revenues of $1.4 billion in 2016 from two marketed ADC agents. Long term sector sales growth can be expected following 2 new approvals in 2017 and a steadily expanding pipeline which now includes 7 candidates in phase III trials. There are 32 companies active in the sector. Public investors remain interested in the space and are looking for next generation additions that will improve both the efficacy and safety of first generation drugs, as evidenced by Mersana’s $400 million IPO. We anticipate our next generation technology, once validated, will make BlinkBio an attractive asset to investors and potential acquirers alike

Management Team Dr. Colin Goddard Ph.D., Chairman and CEO (see above under presenter)

Dr. Maneesh Pingle Ph.D., President has been part of the leadership team since the inception of BlinkBio in 2015 and oversees business development and operations. He brings a multidisciplinary scientific background with training in pharmacy, medicinal and nucleic acid chemistry and molecular biology. Dr. Pingle received his Ph.D. from Purdue University and his Bachelor’s degree in Pharmacy from the Bombay College of Pharmacy (India).

Dr. Jutta Wanner Ph.D., VP Research has also been part of the leadership team since inception and is an experienced pharmaceutical industry executive having joined BlinkBio from Roche in Nutley, NJ where she was a co-lead in discovery chemistry. She brings expertise across multiple therapeutic areas including oncology, inflammation and virology. Dr. Wanner received her PhD from the University of Kansas and conducted her postdoctoral training at The Scripps Research Institute in San Diego.

Financial Forecasts BlinkBio has raised $10.2 million to date and intends to secure additional funding through fees and milestones from technology and project partnerships and from a $15-20 million Series B round planned for 1H2018. The company is pre-commercial and does not expect product sales revenue within the next 5 years. In 2017 the company will have estimated expenses of ~$4 million, approximately 75% of which is committed to R&D. We expect Series B funding to primarily support lead candidate development through to a Phase I/IIa clinical trial and to largely off-set research expenses through collaborations.

17

NeuroTronik Limited (Main Stage) ℅ NeuroTronik, Inc. 4021 Stirrup Creek Drive Suite 210 Durham, NC 27703-9352 Phone: (919) 883-4155 Fax: (919) 973-0437

Presenter(s) Fred McCoy, CEO and Director Mr. McCoy developed his earlier career with Eli Lilly and Company, and its successor company in medical technology, Guidant Corporation. Among his general management roles were President, Guidant Japan and Asia Pacific Operations, and President, Guidant Cardiac Rhythm Management. A native of Laurinburg, North Carolina, Mr. McCoy graduated as a Bachelor of Science in Business Administration from the University of North Carolina at Chapel Hill in 1979. He graduated as a Master of Management from the Kellogg School of Management at Northwestern University in 1981.

Company Profile NeuroTronik Limited is a development-stage, venture-backed medical technology company pioneering a unique therapy approach for the hemodynamic management of patients who present to the hospital due to worsened symptoms of heart failure. The therapy is Cardiac Autonomic Nerve Stimulation (CANS). NeuroTronik CANS Therapy® is designed to improve clinical and economic outcomes for patients, physicians, hospitals, and payers. The vision is to create a new trajectory for people with heart failure. Therapy development has been brisk; the clinical experience is substantial and promising. The Series A (May 2013, US $13.1 million) Milestones were met. The Series B Preferred Stock Financing (April 2017, US $23.1 million raise) is designed to fund the work through to CE Mark approval.

Product and Technology NeuroTronik CANS Therapy is an entirely new medical technology approach in the context of Acute Heart Failure Syndrome (AHFS) in the hospital. The therapy is transvenous, electrical, and direct. The system consists of a single-use NeuroCatheter™, delivered percutaneously, positioned in a blood vessel just above the heart, and a reusable NeuroModulator™, placed bedside. Through cardiac autonomic nerve stimulation, the NeuroTronik CANS Therapy System enhances cardiac contractility without raising heart rate. The clinical impact is to enhance perfusion, improve hemodynamics, and potentiate diuresis. NeuroTronik CANS Therapy is designed to be used in conjunction with, and complementary to, medical therapy. Patients should feel better sooner, spend less time in intensive care, be able to leave the hospital sooner and drier, and be readmitted within 30 days less frequently.

Market Potential Acute Heart Failure Syndrome (AHFS) in the hospital is a major focus of medical guidelines and health policy. It is the #1 cause of hospital admissions in older adults.1 In global reported markets, there are 3.3 million annual hospital admissions for AHFS.2 The global annual economic burden of heart failure is US $65 billion.3 The AHFS hospital admission is both complex and costly – 84% of admissions include complications.4 The treatment location is often Intensive Care. Rigorous physician and nurse involvement is required over several days. Various intravenous drug regimens are employed, some with known negative mortality penalties, some with known side effects that complicate and confound. The treatment objectives are to survive, warm, and decongest the patient. Worsened renal function occurs in 1 in 4 admissions.5 Establishment of an appropriate oral drug regimen is required prior to discharge. Unfortunately, despite best efforts, 24% of patients discharged are readmitted within 30 days.6 Clearly, there is large and valuable room for improvement in clinical tools, methods and outcomes.

18

Management Team Fred McCoy, CEO (presenter) Steve Masson, Sr. VP, R&D, CTO, is a senior executive with over 35 years of experience in the medical technology business. During that period, he has served in general management and Research and Development (R&D) management roles in both early stage startup companies and revenue-driven operations. Jeff Bell, CFO, is an experienced senior executive with over 29 years working in public accounting and in private industry. Mr. Bell spent over 19 years in public accounting where he assisted clients in various industries with their tax and accounting needs, which included tax compliance and planning, audit and assurance services as well as operational analysis, litigation support and assistance with mergers and acquisitions. Mr. Bell is a partner with the firm Rankin McKenzie, one of the Southeast’s largest and most trusted outsourced executive management firms.

Financial Forecasts

The NeuroTronik annual revenue opportunity in global developed markets is US $6.9 billion. The initial target patients are those with diminished ejection fraction exhibiting high congestion, accompanied by low perfusion and/or poor response to diuretics. NeuroTronik therapy is designed to spare patients of inotropic and

vasopressor drug therapies, enhance diuretic and vasodilator drug therapies, and facilitate establishment of the indicated oral drug regimen. NeuroTronik CANS Therapy should help physicians move the patient rapidly out of acute distress, on towards recovery, and out of the hospital. Revenue growth will be driven by platform, geographic, and claims expansion.

1 Cowie MR, Anker SD, Cleland JG, et al. Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Failure 2014; 1: 110–145.

2 Ponikowski P, Anker SD, AlHabib AF, et al. Heart failure: Preventing disease and death worldwide. White paper from the European Society of Cardiology 2014.

3 Cook C, Cole G, Asaria P, et al. The annual global economic burden of heart failure. Int J Cardiol 2013. http://dx.doi.org/10.1016/ j.ijcard.2013.12.028.

4 HCUPnet. Healthcare Cost and Utilization Project (HCUP). 2013. Agency for Healthcare Research and Quality, Rockville, MD. http://hcupnet.ahrq.gov/.

5 Stevenson LW, Management of Acute Decompensation. In: Mann DL, ed., Heart Failure: A Companion to Braunwald’s Heart Disease. Saunders; 2004: 579–593

6 Krumholz HM, Merrill AR, Schone EM, et al. Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and Readmission. Circ Cardiovasc Qual Outcomes 2009; 2: 407-413.

19

Spyryx Biosciences, Inc. (Main Stage) 801-10 Capitola Drive Durham, NC 27713 Phone: (919) 899-9399 www.spyryxbio.com contact@spyryxbio.com

Presenter Timm Crowder, Ph.D., SVP Operations, came to Spyryx from GlaxoSmithKline where he was most recently Director of Advanced Manufacturing Technology, leading innovation in the areas of aerosol and dry powder inhaler release testing, electronic inhalers and particle engineering technologies. Earlier in his tenure at GSK, he contributed to the development of manufacturing systems and processes for GSK’s current asthma and COPD products. Prior to GSK, Timm was co-founder and Chief Technology Officer of Oriel Therapeutics, an inhaler technology company launched to commercialize device designs he developed during his graduate research. Oriel was subsequently acquired by Sandoz Pharmaceuticals. Timm earned his PhD in Biomedical Engineering from UNC-Chapel Hill and has degrees in Physics from North Carolina State University and Davidson College.

Company Profile Spyryx Biosciences is pioneering the use of inhaled peptides to treat severe pulmonary diseases where mucus accumulation and obstructions are key to disease progression. Spyryx was founded to advance mimetics of SPLUNC1, the natural allosteric regulator of ENaC that is dysfunctional in Cystic Fibrosis. The breakthrough discovery of the role of SPLUNC1 was made by Spyryx’s scientific founder, Dr. Robert Tarran (UNC Marsico Lung Institute). Spyryx operates as a semi-virtual biopharmaceutical company leveraging expertise of a small team of employees and consultants with experience in CF, clinical operations and respiratory product development and manufacturing. Spyryx’s lead program, SPX-101, is in Phase 2 testing for CF. Programs using SPX-101 and other peptides for additional indications are in pre-clinical development.

Product and Technology Spyryx’s lead investigational product is an inhaled peptide in clinical development to treat CF-related lung disease for all CF mutations. SPX-101 has demonstrated compelling evidence of the ability to enhance airway liquid volumes in CF patient cells and to restore mucus clearance in animal models of dehydration induced lung disease. SPX-101 specifically targets epithelial sodium channels (ENaC) on the airway surface, causing reduction in channel density by cellular internalization. This novel mechanism mimics the airway’s normal regulation of ENaC surface density, decreasing absorption so that fluid is retained on the airway surface. Enhancing fluid levels restores hydration to the resident mucus and promotes its clearance via airway cilia, a process called mucociliary clearance. Building on the strength of preclinical and toxicology data for SPX-101, Spyryx initiated clinical development, completing Phase 1 studies in healthy volunteers and subjects with CF. These studies indicated a safety and tolerability profile for SPX-101 supporting further investigation. A Phase 2 efficacy study in people with CF is now enrolling for SPX-101 in Canada, the United Kingdom, France, Portugal and Italy: HOPE-1 – Hydration for Optimal Pulmonary Effectiveness (www.clinicaltrials.gov/show/NCT03229252; https://www.cysticfibrosis.org.uk/get-involved/trialstracker/2017/09/99066 ). HOPE-1 is a 28-day placebo-controlled study with the goal of establishing safety and efficacy for SPX-101 in the treatment of CF. Cystic Fibrosis is a genetic disease that impacts the body’s ability to regulate the flow of salt and water across epithelial membranes, resulting in loss of fluid volume. The respiratory tract is one of the most profoundly affected, causing dehydration-induced lung disease that begins with depleted airway surface liquid and

20

accumulations of dry, sticky mucus and leads to chronic inflammation, recurrent infections, and reduced ability to breathe. Airway fluid dehydration in CF is mediated by ENaC, which are dramatically over-expressed in this disease.

Financial Spyryx is financed by top-tier VC firms Canaan Partners, Hatteras Venture Partners and 5AM Ventures.

21

Advanced Chemotherapy Technologies, Inc. (Early Stage) 2301 Stonehenge Dr. Suite 115 Raleigh, NC 27615 Phone: (919) 917-7324 (o) Phone: (919) 368-0522 (c) www.advancedchemotech.com tvoiers@advancedchemotech.com

Presenter Tony Voiers - CEO, has over 25 years experience in the medical device industry with most of his career spent in general management, new product development, and operations. Currently, Tony is CEO of Advanced Chemotherapy Technologies (ACT). In this role Tony has secured $3M in financing and is leading the company to its first human clinical trial for treatment of pancreatic cancer. Prior to ACT, Tony was founder and CEO of Novocor Medical Systems were he raised over $2M in financing and led the organization to FDA clearance of Hypocore™, a medical device that chills IV fluids to induce therapeutic hypothermia in cardiac arrest patients. Prior to Novocor, Tony worked at Ethicon/Closure Medical were he served in several roles including Director of Operations, Director of Product Development, Director of R&D and Managing Director for the Raleigh facility.

Company Profile Advanced Chemotherapy Technologies (ACT), a Delaware C-corp based in North Carolina’s Research Triangle Park, has developed a novel system for local delivery of chemotherapies directly into poorly vascularized tumors. In many cancers (such as pancreatic, head & neck, inflammatory breast, and others) the tumor is encased in avascular fibrous stroma that limits the penetration of intravenously delivered chemotherapies. In these cases it is common to try to overcome the poor vascularity by delivering massive doses of systemic chemotherapies, which result in devastating side effects that force many patients to stop treatment. ACT has overcome these issues by developing a surgically implanted iontophoresis delivery system that delivers higher doses of chemotherapies directly into the tumor tissue while lowering systemic toxicity. This technology advancement enables ACT to develop new treatments for existing chemotherapies and new delivery options for clinical stage compounds, especially promising new compounds that may be facing difficulty due to systemic toxicity.

The company was founded at the University of North Carolina at Chapel Hill by Professors Joseph M. DeSimone, PhD and Jen Jen Yeh, MD, where they completed six extensive pre-clinical studies showing significant tumor reduction in PDX pancreatic cancer and inflammatory breast cancer models, leading to four publications. ACT's first indication will be the treatment of locally advanced non-resectable pancreatic cancer with gemcitabine. The company has met with the FDA to gain agreement on its clinical and regulatory strategy and has secured $2.4M in non-dilutive funding and $600K in seed funding. ACT’s next milestone will be the initiation of a First-in-Human clinical trial in 2019. ACT is seeking investors and strategic partners that can help carry this promising local drug delivery system through subsequent clinical trials, FDA approval, and to commercialization.

Product and Technology ACT is in development of a surgically implanted iontophoresis local drug delivery system that delivers higher doses of chemotherapies directly into the tumor thereby lowering systemic toxicity. This technology enables ACT to develop new treatments for existing chemotherapies and to salvage promising new compounds that were halted at the clinical stage due to toxicity. ACT's first indication will be the treatment of locally advanced non-resectable pancreatic cancer with gemcitabine. ACT’s iontophoresis chemotherapy delivery device has been designed to be surgically implanted on the pancreas directly over the tumor area with tubing that connects the device delivery head to a skin port. Chemotherapy solution is infused through the skin port to the delivery head on the pancreas and a DC Power control unit is attached to electrical leads in the skin port and counter electrode on the patient’s back. Current is then applied, which drives the chemotherapy out of the delivery head and directly to the tumor area via an electromotive force. It is anticipated that upon completion of an 8-week chemotherapy regime, CT imaging will be used to determine the resectability of the tumor. If resectable, then both the tumor and the device will be removed. If the patient has responded to the therapy, but the tumor has not yet regressed to the point that surgical removal is possible, therapy may be continued.

22

Management Team Tony Voiers - CEO, bio shown above

William Daunch, PhD – CTO, has 17 years of experience in medical device, combination product, and biomaterials research, development and commercialization, preceded by 10 years of industrial chemical research and development. Most recently William served as Senior Director of R&D and Site Manager of Allergan Medical in Medford MA, overseeing a team of 120 people responsible for medical technology manufacturing, operations, quality, regulatory, clinical affairs and R&D. Before Allergan, William served as Director of R&D for J&J, responsible for new product development for Ethicon Products. With 11 publications and 7 patents to his credit, William is responsible for numerous commercially successful polymer and materials-based innovations in the automotive, construction and aerospace industries and has had similar success developing and commercializing innovative class II and class III medical devices and combination products for wound healing, soft tissue repair and reconstruction, medical aesthetics, as well as orthopedic, laparoscopic and cardiovascular surgery.

Financial Forecasts ACT’s financial forecast for the next 5 years is driven by its clinical and regulatory strategy that the company developed in conjunction with the FDA. This strategy includes 3 sequential clinical trials; the first of which will start in 2019 and focuses on the safety of local chemotherapy delivery with our device. This First-in-Human trial is funded through a NIH SBIR grant, but subsequent trials will need investor and/or strategic funding. We anticipate our Phase 2 trial to begin in 2021 and require ~$7M in capital, followed by a Phase 3 trial beginning in 2023 and requiring ~$30M in capital.

23

Entac Medical Inc. (Early Stage) 1775 Moriah Woods Suite 6 Memphis, TN 38117 Phone: (901) 292-3420 www.entacmedical.com blyons@entacmedical.com

Presenter Buddy Lyons, Founder and Chief Executive Officer, has been involved in healthcare investing and capital formation for over 20 years on both the buy- and sell-side as well as startup operations. Lyons has been the CEO of Entac since its inception. Prior to that, he founded the Lyons Share Group, a consulting firm that assists small healthcare companies and advised money managers on the healthcare sector. He has served as CFO for two startups and established healthcare companies and managed $3B in healthcare equities for Wachovia Asset Management. He has an MBA from Duke University.

Company Entac Medical is developing noninvasive devices for predictive and diagnostic medicine based on a novel, patented, platform technology, Audio Spectral Analysis. The flagship application, PrevisEA, is clinically proven to predict post-operative ileus (POI) in surgical patients. Predicting POI is a $2 billion global market. POI is acute paralysis of the GI tract that occurs 2-6 days after surgery causing nausea and vomiting and distended abdomen and pain. About 25% of colorectal surgery patients develop POI. Not knowing which patients are at risk increases length of stay, readmission rates and cost of care. POI is one of the most common reasons for readmission with rates over 20%. The Previs Audio Spectral Technology (PASAT) was invented by a prestigious Chief of GI Surgery. It is a noninvasive, self-contained, disposable device attached to the patient’s abdomen. Using proprietary algorithms, PrevisEA stratifies patients based on risk of developing POI with almost 100% accuracy. Management believes patient and cost benefits will include the following:

• Directs appropriate treatment for better patient outcomes

• High risk patients treated appropriately reducing stays as much as 4-6 days

• Low risk patients discharged 2-4 days earlier

• 25% readmission rates for discharged patients are reduced to nearly zero

• Estimated cost savings for hospitals annually of $2.2M per 300 cases Better patient outcomes and reducing costs are expected to drive widespread adoption as CMS links reimbursement to patient care metrics and hospitals begin to tie surgeon compensation to discharge and readmission rates. Entac believes Previs will capitalize on these market dynamics. Entac is gearing up to accelerate commercialization through filing a 510(k) and conducting a short-term 150-patient trial for a de novo application to strengthen the label for the prediction of postoperative ileus. Longer term, Entac intends to develop audio spectral analysis technology as a predictive/diagnostic in other applications of GI medicine.

Product and Technology PrevisEA is a noninvasive, disposable, self-contained device placed on the abdomen after surgery that records and analyzes intestinal sound for a specific audio signature, MH4. This signature is highly correlated with the development of POI. POI develops 2-6 days after surgery and no demographic or other patient data has ever proven to provide a prediction of which patients are more likely to have a POI. PrevisEA makes the prediction by postop hour 12 by counting the number of MH4 events each hour. This enables a surgeon sufficient time for appropriate postoperative care determinations such as whether to begin feeding a patient and the appropriate time

24

to discharge without concern for POI developing at home, improving patient outcomes, reducing length of stay and readmissions as well as overall cost of care.

Market Potential Although the customers for PrevisEA are surgeons and hospitals; ultimately, the use of PrevisEA will be driven by patient volume. Globally, for all surgical uses of PrevisEA, management estimates 10-15 million patients annually could benefit from its use. In the US, PrevisEA would apply to 2 million in colorectal surgery and 2.5 million in the EU. The market potential in those two market is estimated to be $2 billion in colorectal surgery alone. Additional surgery types could double the market size. Prediction and diagnosis of additional GI conditions creates additional revenue potential.

Manangement Team John W. Cromwell, M.D. FACS FASCRS, Chief Medical Officer is a nationally recognized colorectal surgeon and is currently Professor of Surgery, Director of GI, Minimally Invasive and Bariatric Surgery and Associate Chief Medical Officer for Surgical Quality at the University of Iowa. He is a leading authority on Predictive Medicine and the inventor of audio spectral analysis. Dr. Cromwell obtained his medical degree and general surgery training at the University of Minnesota Medical School where he was honored with the Minnesota Medical Foundation Distinguished Resident Teaching Award. He obtained his Colon & Rectal Surgery Fellowship training at the University of Texas in Houston, TX in 2003. M. Andrew Forsdick, Chief Financial Officer, began his career in public accounting with Coopers & Lybrand. Leaving there in 1998, he worked as a financial advisor. Mr. Forsdick formed Addison Capital Advisors in January 2004 for the purpose of providing CFO services to early stage and start-up companies. In January 2011, he began serving as CEO of one of the portfolio companies, Vivicast Media & Entertainment Group, Inc. (f/k/a Telco Television Corporation). In 2015, he formed Sage Business Advisors which provides C-suite services (primarily CFO, CMO and COO) to primarily early stage and startup companies. In addition, Sage has formed an angel investor-based VC fund.

Financial Forecasts Entac is raising $2 million to accelerate regulatory, product development and commercialization activities. These activities include the following:

• Filing a 510(k)

• Completion of a pivotal clinical trial to file an FDA de novo application to strengthen PrevisEA prediction label

• Further product development of PrevisEA and new predictive/diagnostic applications

• Building appropriate sales and marketing infrastructure to begin commercialization

(In $millions) Assumes Entac markets alone

2018 2019 2020 2021 2022

Revenue $0 $0 $16.2 $43.4 $82.5

EBITDA -0.468 -1.618 -1.75 0.866 13.806

Pre-Tax Income -0.468 -1.618 -1.75 0.866 13.806

25

EternaTear, Inc. (Early Stage) 5650 Six Forks Rd #202 Raleigh, NC 27609 919-241-3200 www.Med1Ventures.com

Presenter Joe Huber, COO Joe worked as a product manager for 6 years, managing a $10M portfolio of healthcare products. While earning his MBA at Duke, he consulted for an ophthalmology startup, worked as a venture fellow with IDEA Fund Partners, and spent his summer internship at Silicon Valley Bank’s Bay Area life science practice.

Company Profile EternaTear is developing a next generation therapy for the $2B over-the-counter dry eye market. Patients with even moderate dry eye can suffer from debilitating symptoms that lead to a drastically reduced quality of life, including lost time at work and even depression. Current treatment options are limited, and most patients rely on over-the-counter eye drops for temporary relief. But because they neither treat the root cause, nor appropriately address the symptoms, current products on the market fail to provide adequate relief and must be reapplied as often as 6-12 times every day.

Dry Eye affects 45M Americans, causing symptoms that range from mild burning and irritation to unbearable pain. While there are prescription drugs available (Restasis and Xiidra), both are only effective for dry eye resulting from inflammatory immune responses, causing these drugs to work in <15% of cases. Evaporative and many aqueous-deficient dry eye sufferers will see no relief from these drugs, which is why most DES sufferers rely on an OTC solution for relief of their symptoms.

The EternaTear team has decades of experience and have developed several dry eye drug and device therapies, including some of the top products on the market. Our advisory team is filled with industry veterans, and the top key opinion leaders in the fields of optometry and ophthalmology. Using our deep experience and broad network, we are developing the most complete and longest lasting artificial tear on the market and aim to bring this breakthrough solution to the 320 million people around the world who suffer from dry eye.

Product and Technology The tear film is only about 10 microns thick, yet it is made up of 3 discrete phases (lipid, aqueous, and mucin) as well as interstitial layers that bind them each together and allow the entire film to remain on the eye. A deficiency in any of these components can disrupt the delicate homeostasis of the entire tear film, resulting in dry eye. Current products fail to supplement all layers of the tear film, causing their efficacy to be sporadic and short-lived.

Based on decades of pioneering research in Dry Eye and portfolio of patents, EternaTear is an artificial tear that supplements all layers of the tear film using previously unrecognized mechanisms that enable its lubricating properties to remain on the eye much longer than current products. Because the formulation contains the components necessary to supplement each layer of the tear film and their interstitial layers, it will provide relief for patients with a wide variety of underlying causes. It lasts up to 4x longer than what’s currently available, so relief can be achieved with only 1 or 2 applications per day, giving patients all day comfort and freedom from the hassle of constantly applying eye drops.

EternaTear is being developed as preservative-free dry eye product that supplements all aspects of the tear film. It will be effective for all dry eye patients, no matter the underlying cause. Patients with aqueous deficiency, LASIK complications, and evaporative dry eye (e.g., Meibomian Gland Dysfunction) will all see lasting comfort from their dry eye symptoms. Further, EternaTear’s proprietary formulation reduces the number of applications per day by a factor of 2x-10x. These improved performance attributes eliminate the need for product switching and reduce the risk of corneal damage, ultimately giving patients lasting relief from the painful symptoms of dry eye.

26

Market Potential Because of the regulatory hurdles & capital requirements associated with developing Rx treatments, EternaTear’s focus is on the $2B global OTC Dry Eye market, which is growing at 6-12% in key geographies and will hit $2.4B by the time EternaTear is ready to launch in 2021, according to a 2016 MarketScope report and industry sources. The artificial tears previously developed by members of the EternaTear team are estimated to finish 2018 at $350M in total revenue. The performance profile and the non-preserved designation of the product we’re developing creates a global opportunity larger than its closest competitors. When a pharmaceutical partner launches this product, it’s reasonable to expect it to capture 1.5% market share in its first year and grow organically and through subsequent market entries. If EternaTear follows a similar adoption curve to recent product launches, by year three it would hit >$50M and by year five hit $80M-$100M in global sales. Year 5's sales would equate to <4% global market share capture, a reasonable target for an incumbent player with strong marketing and distribution infrastructure. EternaTear will command an average selling price in the upper quartile of the market and at scale would produce an 80% gross margin.

Management Team Tim Willis, CEO Tim has worked in Dry Eye for more than 20 years. In that time, he developed what would become the Soothe XP product line for Bausch and Lomb, was involved in the development of Systane Balance for Alcon. Most recently, he was the founder, inventor, and CEO of TearScience, an RTP-based device company started to diagnose and treat Meibomian Gland Dysfunction, the leading cause of Dry Eye. TearScience raised $134M and was acquired by Johnson and Johnson.

Joe Huber, COO Joe worked as a product manager for 6 years, managing a $10M portfolio of healthcare products. While earning his MBA at Duke, he consulted for an ophthalmology startup, worked as a venture fellow with IDEA Fund Partners, and spent his summer internship at Silicon Valley Bank’s Bay Area life science practice. Diethart Reichardt, Chairman Diethart is the former President of Allergan’s Consumer/OTC Products division, a global business focused on contact lenses, contact lens care, ocular lubricants, and dry eye products. He has 35 Years of ophthalmology industry expertise in devices, pharmaceuticals, and OTC.

Financial Forecasts We are raising $4M develop the completed product, conduct safety and market clinical studies, develop manufacturing processes, and clear regulatory in the US and EU. This allows us to be an attractive acquisition target in less than 3 years. Based on previous products developed by our team, we expect EternaTear to be able to capture 1.5% of the market in the first year after launch, ramping to $100M in global revenue by year 5.

0.0%

1.0%

2.0%

3.0%

4.0%

5.0%

Y E A R 1 Y E A R 2 Y E A R 3 Y E A R 4 Y E A R 5

US

MA

RK

ET

SH

AR

E

Adoption of Ar t i ficial Tears in US

Systane Balance

Refresh Optive Adv.

Soothe XP

27

Innovative Med Concepts (Early Stage) 1837 Commons North Drive Tuscaloosa, AL 35406 Innovativemedconcepts.com 917-693-0974

Presenter William L. Pridgen, MD - CEO/Founder Surgeon and Clinical research physician collaborating with the University of Alabama since 2007 Richard A Burch -President Prior to IMC: Senior VP for Pfizer (30 years) in charge of a number of commercial Divisions, then joined UCB as Vice President and General Manager leading the Central Nervous System Business Unit.

Company Profile IMC, is a development stage Biotech Company focused on identifying and developing novel, pharmaceuticals directed at major unmet medical need. The Company’s lead product, IMC-1, is a novel, first-in-class fixed dose combination oral pharmaceutical product to treat fibromyalgia (FM), a devastating chronic pain condition. The Company has demonstrated that recurrent reactivation of virus (HSV-1) infection triggers an immune response that results in fibromyalgia, a finding that was not known before. IMC-1 targets the underlying cause of fibromyalgia and other related conditions. The Company will proceed to a FM Phase-2b confirmatory study prior to advancing to Phase 3, NDA and commercialization. IMC is currently evaluating partnering opportunities while advancing the development of IMC-1 and raising the capital required to fund this program. IMC is currently offering a Series C equity raise of $20M which will propel the Company to its next phase of growth.

Product and Technology IMC has completed a double-blind, placebo controlled, randomized proof-of-concept, Phase 2 study in 143 patients that has confirmed substantial advantages of IMC-1 over the currently used products and standard of care. This data was published in the Journal of Pain Research and presented at the American College of Rheumatology annual meeting. FDA has stipulated that fibromyalgia is a serious disease with major unmet medical need and has granted IMC-1 Fast Tract status, reflecting the potential that IMC-1 will deliver substantial improvement in treatment outcomes. The Company held an end of Phase 2 meeting with the FDA and has received agreement from FDA to initiate the Company’s Phase 2b/3 clinical trial program. The Company has demonstrated compelling evidence that IMC-1 is likely to be effective in other conditions that share the same underlying pathophysiology seen in FM, such as Irritable Bowel Syndrome. Central sensitization to pain seen in FM is secondary to a combination of genetic and environmental factors that render patients susceptible to developing the widespread chronic pain seen in fibromyalgia. Fibromyalgia patients exposed to significant life stressors result in an altered immune response. The cyclical process of virus reactivation and lytic infection of HSV-1 perpetuates the symptoms of FM. IMC-1 interrupts the recurring immune activation by suppressing HSV-1 virus, which in turn suppresses the abnormal stress response. The demonstrated efficacy, safety and tolerability of IMC-1 differentiate it from current standard of care and competitive near-term pipeline. The reduction in pain score shown in the Phase 2 study exceeds current FDA approved FM products. Adverse events seen with current FM approved drugs were seen less frequently in the IMC-1 treated group, as compared to the placebo group. The lower adverse events and higher adherence rates associated with IMC-1 treatment are expected to lead to overall improvement in outcomes for FM patients. Intellectual Property: The Company has multiple layers of patent protection for IMC-1. This includes Composition of Matter patent and two Method of Use patents for fibromyalgia, IBS and CFS along with a pending Synergy patent in the US. IMC-1 has patent protection in all major Pharma markets equaling 90% of the global market. Exclusivity with all patents is through 2033.

Market Potential FM approved products, Lyrica and Cymbalta, together had peak annual sales of approximately $10B, with net US FM annual sales directly contributing over $1.1B. Currently approved therapeutics and the near-term pipeline are directed at the alleviation of heightened pain sensitivity symptoms in FM patients. IMC- 1 represents the first effective treatment for fibromyalgia to enter the clinic with a mechanism of action designed to treat an underlying cause. Fibromyalgia affects 2% to 8% of the US population and is the second most common “rheumatic disorder”, second to osteoarthritis. Approximately 4 million FM patients are diagnosed, with ~2 million patients actively treated. Based on primary market research by Triangle Insights Group and Lumleian, IMC-1 is projected to have a peak adoption rate of 24%, use as a first-line treatment and favorable pricing and access potential. Both forecast

28

blockbuster potential for fibromyalgia in the US alone. Patients are currently most often treated by Rheumatologists, Pain Specialists, Neurologists and Primary Care.

Management Team CEO & Founder, William L. Pridgen, M.D. A 25-year general surgeon who got his undergraduate degree from Rhodes College. He attended the medical school and completed his surgical residency at the University of Tennessee College of Medicine. Dr. Pridgen is board-certified in general surgery and has spent nearly 20 years researching effective treatments in IBS, FM, and MECFS. Dr. Pridgen is the founder of IMC and has spearheaded IMC's research. President - Richard A. Burch 30 years with Pfizer where he held the position of Senior VP in charge of a number of Divisions in the U.S., including the Arthritis, Pain and Metabolics. Mr. Burch became Vice President and General Manager of the Central Nervous System Business Unit of UCB, a multinational biopharmaceutical company based in Brussels. Mr. Burch has experience in launching over 20 pharmaceutical products, including major Blockbuster brands such as Lyrica, as well as the turnaround of several pharmaceutical products, including Lipitor. Responsible for teams as large as 6,500 people with revenues over $11.5B. Moreover, he has negotiated co-promotion and licensing deals and has established and leveraged complex business partnerships. Mr. Burch received a Bachelor’s Degree in Marketing from the University of Alabama and certification from the Finance and Accounting Department of Columbia University’s Graduate School of Business. Ian R. Ferrier, MD PhD Business Development & Medical Lead Dr Ferrier has more than thirty years of research and development, market development, public policy, corporate governance, senior management and Board of Director experience in Biopharmaceutical, healthcare and healthcare related companies. This experience encompasses ethical pharmaceuticals, diagnostics, devices, generic drugs, biologicals, animal health and health informatics, as well as policy and economics as these relate to healthcare. As managing Partner at Sibelius, Dr. Ferrier established a widely recognized and successful track record in crafting corporate alliances and securing capital structures in support of these industries, including the raising of equity and debt capital, and the execution of transaction-related funding. Dr. Ferrier has also held senior management positions in major multi-national pharmaceutical companies. R. Michael Gendreau, M.D., Ph.D. Dr. Gendreau consults as IMC's Senior Medical Officer. He received his M.D./Ph.D. in medicine and pharmacology from The Ohio State University College of Medicine. Dr. Gendreau previously worked at Cypress Bioscience, Inc. for almost 16 years. During that time, he held various positions including Vice President of Research and Development and Chief Medical Officer. Dr. Gendreau spearheaded bringing Savella from its NDA inception to approval. He has more FM trial experience than anyone in the world. Kevin A. Phelan, PH.D. Dr. Phelan consults as IMC’s Regulatory lead and has more than 20 years of experience in regulatory affairs and clinical development, including being the regulatory lead for the treatments of fibromyalgia and pain at Pfizer. Dr. Phelan had a 20-year career at Pfizer in Global Research and Development, Clinical Development, and Worldwide Regulatory Affairs. Dr. Phelan earned a PhD in Neurobiology from The University of Chicago.

Financial Forecasts IMC is currently offering a Series C equity raise of $20 - 25M which will fund IMC-1’s confirming Phase 2b study, and propel the Company to its next phase of growth. The Phase 2b will count toward the Phase 3 requirements and significantly de-risk the asset. Independent commercial assessments project that IMC-1 represents a blockbuster opportunity >$1B peak annual sales. Revenue is expected in second quarter of 2022 with profitability coming in the second full year of commercial operation.

29

IQuity, Inc. (Early Stage) 209 10th Avenue South, Suite 404 Nashville, TN 37203 Phone: (855) 899-9551 Fax: (800) 859-8411 www.iquity.com info@iquity.com

Presenter(s) Dr. Chase Spurlock, Ph.D., Founder & CEO, has day-to-day oversight of all aspects of IQuity ensuring the vision and mission are realized. He has extensive experience in autoimmune disease and the creation of machine learning technologies. He is expanding the company’s analytics offerings to deliver accurate clinical insights that speed diagnosis and treatment decisions. Dr. Spurlock is a Phi Beta Kappa graduate of The University of the South and received his PhD in immunology from Vanderbilt, where he also serves on the faculty.

Company Profile IQuity is a data analytics company leveraging machine learning to predict, detect, monitor, and stratify severity of disease for healthcare stakeholders, thereby improving patient outcomes and lowering costs. IQuity creates tailored models for disease management at scale, applying comprehensive customer insights and data science approaches to solve complex problems. Since its founding in 2015, IQuity has commercialized three RNA-based diagnostic blood tests, built a COLA-accredited CLIA-certified lab, and further developed its data science expertise. The company is now expanding its mission with a predictive analytics platform to deliver insights regarding autoimmune disease risk in large patient populations. IQuity leverages its competencies to bring about true precision medicine to the market.

Product and Technology IQuity offers an analytics platform capable of predicting an oncoming diagnosis, identifying misdiagnosis, stratifying severity, and monitoring disease progression using a variety of data sources including healthcare claims data, EHR data and datasets representing social determinants of health. IQuity initially used machine learning to develop and commercialize three highly accurate genomic RNA blood tests to identify autoimmune disease and related conditions at the earliest signs of symptoms, including multiple sclerosis (MS), Crohn’s disease and ulcerative colitis (IBD), IBS, and fibromyalgia. IQuity owns and has protected its intellectual property with four filed patents and three PCTs. With over a decade of autoimmune disease research and development applied to genomic data, IQuity is now well positioned to apply a similar approach to population-level data to predict and monitor disease. Two early pilot studies using commercial healthcare claims data on 20M lives predicted MS up to eight months in advance of a conventional diagnosis and identified misdiagnosis over >90% accuracy. IQuity’s unique value proposition is its ability to leverage its knowledge of autoimmune disease combined with over a decade of machine learning on large genomic datasets.

Market Potential In 2017, the entire healthcare analytics market represented a $9 billion opportunity, with most of that spent by hospital/health systems, and it is expected to grow to over $30B by 2022. IQuity’s healthcare analytics niche, Clinical Decision Support Systems, is projected to grow to almost $5B by 2021. IQuity’s core customers: risk-based payers, self-insured employers (SIE), and care management partners will pay for the service on a recurring SaaS basis, whereby the PEPM/PMPM price will reflect the size of the population served. IQuity can achieve $260 million of annual revenue by 2022 based on a pricing model that demonstrates an ROI of 5-10x and assumes less than 10% penetration of the addressable market. IQuity’s target customers include risk payers with 40,000-1M+ covered lives, SIEs with at least 10,000 covered lives, and care management providers who serve both types of payer. In addition, integrated delivery networks, HIEs and ACOs bearing risk on a large number of covered lives will be targets.

30

IQuity’s unique advantage is the use of population-level and genomic datasets to predict, detect and monitor disease. Very few competitors, if any, target autoimmune disease. The analytics platform predicts disease months in advance of a conventional diagnosis, stratifies disease severity over time, and is capable of monitoring autoimmune disease and associated comorbidities in real time. IQuity’s existing genomic blood tests are also a differentiator in that they can be deployed by a provider to confirm an alert from the analytics platform. None of IQuity’s competitors offer genomic confirmation. The healthcare data analytics sector is crowded. Most competitors offer standard, actuarially-based tools to deliver risk stratification, but few companies combine multiple datasets to predict disease onset, stratify risk based upon in-depth knowledge of disease and disability progression and deliver results tailored to individual geographies and populations. IQuity’s most direct competitors include: Base Health, HealthCatalyst, Optum, and HBI Solutions.

Management Team Dr. Chase Spurlock, Ph.D., Founder & CEO, established IQuity to transform the diagnosis and treatment of autoimmune disease. He has led NIH-funded projects to create new tools to diagnose and monitor these conditions and has identified therapeutic targets for disease management. His work leverages a diverse set of data science approaches to examine genomic and population-level data to create predictive and prescriptive population analytics capable of improving patient outcomes and lowering healthcare costs. Julia Polk, Chief Strategy Officer & CFO, is responsible for guiding company strategy and positioning the business for scale operationally and financially. She is focused on raising equity capital, establishing revenue and business models, cultivating strategic partnerships and establishing long term relationships to support the growth of the business. Julia’s career in finance spans over 30 years of building companies and mentoring early stage entrepreneurs. She has served as CFO for two early stage companies that were pioneering new industries (employer sponsored onsite child care and healthcare cost transparency) while launching new ventures: Bright Horizons and Change Healthcare, both of which have successful exits. Julia has served in a variety of senior strategic finance and interim management roles, and she’s coordinated the raising of over $40MM in venture, strategic and angel capital. Since June 2012, she has mentored and advised over 100 startup companies in healthcare services, life sciences and technology. She graduated from Vanderbilt University with a degree in mathematics.

Financial Forecasts IQuity is currently in the market with a 5% Convertible Note and has closed $1.5M of a $3.0M financing. Upon the commercial launch of the analytics platform, IQuity will being the process of raising a $5-10M Series A.

Use of proceeds from the Convertible Note and eventual Series A will support build-out its analytics platform, including the necessary personnel and data infrastructure, sales and marketing efforts to develop a customer base and general working capital.

As described above, upon reaching 10% market penetration, revenues could approach $260M annually. The timing of the rollout of new, recurring revenue customers will determine the speed with which these revenue targets are met. As the company scales, expenses will be managed to achieve breakeven within two years from commercial launch. Expected EBITDA margins will be consistent with other SaaS analytics technology companies.

Detailed financial information and related assumptions is available upon request.

31

Neuroene Therapeutics, LLC (Early Stage) 645 Meeting Street, Charleston, SC 29403 Phone: (843) 302-6986 www.NeuroeneTherapeutics.com NeuroeneTherapeutics@gmail.com

Presenter Sherine S. L. Chan, Ph.D., COO is a co-founder of Neuroene Therapeutics. While Dr. Chan is primarily employed at Neuroene, she is also an Associate Professor of Drug Discovery at the Medical University of South Carolina (MUSC), in Charleston, SC. She has been in the mitochondrial field since 1996, first at Murdoch University, Australia, and later at NIEHS/NIH in Research Triangle Park, NC, focusing on a major locus for orphan mitochondrial epilepsies. Her lab group at MUSC has developed new animal models that are part of the platform for screening chemical compounds for difficult to treat neurological diseases. Her research is supported by federal, state and foundation grants.

Company Profile Neuroene Therapeutics is a startup drug discovery company formed in 2015 after the Co-Founders discovered a new class of compounds based on Vitamin K (VK) that improves mitochondrial and neuronal health in multiple animal models of difficult to treat neurological diseases. The company currently consists of 5 people working at MUSC and the South Carolina Research Authority (SCRA) Innovation Center. In the short term the company is using its recently awarded Phase II STTR grant from the NIH to identify the clinical candidate and patient subset for epilepsy. The long-term objective is to develop the VK drug discovery platform to identify clinical candidates for multiple orphan disease development.

Product and Technology Mitochondrial dysfunction is a major cause of many neurological disorders, because the mitochondria produce much of the energy for neurons, as well as factors that induce oxidative stress and cell death. Our novel VK analogs represent a radical departure from previous and ongoing drug development strategies for neurological disorders, by targeting a major underlying cause, energy metabolism, as opposed to merely treating the symptoms of the disorder. Our VK analogs cross the blood-brain barrier, are non-sedating and non-toxic as shown by mouse studies. Current lead compounds have excellent in vivo serum half-life and oral bioavailability. More than 100 VK analogs have been derived and are covered by issued and pending patents aimed at the treatment of numerous neurological disease indications and the corresponding methods. Animal data shows that different analogs are selectively effective in different disease models, such as medication-resistant epilepsy, Parkinson’s Disease, and mtDNA depletion (Alpers) syndrome, an orphan epilepsy syndrome.

Market Potential Our first market is medication-resistant epilepsy. Epilepsy is a chronic disorder defined by recurrent, unprovoked seizures. Over a lifetime, 1 in 26 people will develop epilepsy (50 million people worldwide). In the US, 2.9 million people have active epilepsy and 150,000 people will develop epilepsy annually. A 2015 appraisal (Grand View Research) valued the global anti-epilepsy drug (AED) market at $4.1B. There are 25 AEDs on the market, but 40% of patients are medication-resistant, due to ineffectiveness or severity of side effects. Thus, there is a substantial unmet need for effective, well-tolerated, disease-modifying treatments for epilepsy that target new mechanisms of action. There are two potential AEDs in the pipeline that also target other aspects of energy metabolism – Fenofibrate, which mimics the ketogenic diet, but is burdened by dietary limitations and adverse side effects, and 2-Deoxy-D-glucose, a glycolytic inhibitor that can be cardiotoxic. As our compounds also have efficacy in animal models of a rare pediatric disease known as Alpers syndrome, we may qualify for Orphan Drug Designation and priority review by the FDA, and thus we will pursue this option. Neuroene Therapeutics will seek partnership or acquisition by a large pharmaceutical company following completion of Phase I or I/II studies. As such, the marketing and sales strategy will be dictated by the downstream partner.

32

Management Team C. James Chou, PhD, Co-Founder and CEO. Dr. Chou has bachelor degrees in Economics and Biochemistry (U. Washington), and a PhD in Chemistry (U. Washington). At Scripps, he developed disease modifying treatments for rare mitochondrial neurological diseases – the compound developed for Friedreich’s Ataxia is in Phase II clinical trials. Dr. Chou splits his time between his academic laboratory at MUSC, and Neuroene Therapeutics, where he oversees the business end of the company. Sherine Chan, PhD, Co-Founder and COO. See above, under Presenter. Richard A. Himes, PhD, Chief Scientific Officer. After obtaining his PhD from Purdue, Dr. Himes performed cutting-edge research on redox active compounds in Alzheimer’s disease at Johns Hopkins. Dr. Himes performs much of the medicinal chemistry for the company. Richard Labaudinière, PhD, Advisory Board Member was most recently the CEO of FoldRx Pharmaceuticals, a drug discovery and clinical development company that developed a disease-modifying therapy for TTR amyloid polyneuropathy, and carried this drug (tafamidis/ Vyndaqel ® approved in Europe and Japan) through full Phase III clinical trials. Labaudinière successfully led the merger and acquisition of FoldRx by Pfizer. He was senior VP of R&D at Genome Therapeutics, where he developed Ramoplanin, an antibiotic drug. He also led the early program at Glaxo under a partnership with ICOS to discover, optimize and develop the PDE5 enzyme inhibitor tadalafil (Cialis®, Adcirca®) used for erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia. Karen Lackey, Advisory Board Member was previously the VP and Head of Medicinal Chemistry at Hoffmann-La Roche (USA), and Global VP of Discovery Chemistry at GSK, where she played an active role in the discovery of the dual erbB2/EGFR tyrosine kinase inhibitor, lapatinib (Tykerb ®). She is now the Director for the Arizona Center for Drug Discovery at U. Arizona and is an entrepreneur in early-stage biotech with special interest in platform technologies, such as those outlined by Neuroene Therapeutics.

Financial Forecasts Capital raised to date is $4.2M, all of which are undiluted funds from founder contributions, MUSC, SCRA, Barmore Foundation, or NIH grants (including our recently awarded Phase II NIH SBIR grant for $1.5M). The overall financial goal is to be acquired, to partner with large Pharma, or engage a sublicensee. Neuroene Therapeutics will seek further funds, either venture capital and/or private equity. Two venture capital groups and two large Pharma have recently expressed interest. Non-dilutive funding to support other disease indications, such as NIH SBIR Phase IIb funding, which requires a partner who can match the $3M award over 3 years, are being pursued. With excellent mouse PK data in hand, Neuroene Therapeutics continues to pursue Pharma partners as well as securing Series A funding from early investors for completion of the pre-IND package (GLP pharmacology and toxicology, and chemistry, manufacturing, and controls). In five years, the initiation of Phase I clinical trials is anticipated.

In addition, pursuing orphan indications such as Alpers Syndrome would enable access to the FDA Orphan Products Clinical Trials Grants Program and the first clinical study could be grant-funded. By further de-risking the project, Neuroene Therapeutics’ unique therapeutic strategy will make it an attractive target for investment and potential acquisition by investors and large pharmaceutical companies. The table below represents major investment milestones and inflection points for acquisition, partnership or sublicensing:

Milestone/Inflection Point Estimated Date of Initiation

Estimated Funding Required

Anticipated Sources

Identify clinical lead June 2020 $2M SBIR Phase IIb/Early phase investors

IND-enabling studies and IND-application

June 2022 $2-4M Early phase investors

Phase I/IIa Clinical Trials

December 2022

$7-9M Venture capitalist and pharma

Phases IIb-III Clinical Trials March 2024

$20-30M Large/medium pharma partnership

33

NIRvana Sciences, Inc. (Early Stage) 2 Davis Drive Research Triangle Park, NC 27709 Phone: (919) 354-1053 www.nirvanasciences.com Russell@nirvanasciences.com

Presenter Russell D. Thomas, CEO, is a co-founder of NIRvana Sciences. He was previously Director, New Venture Services in the Office of Technology Commercialization and New Ventures at North Carolina State University.

Company Profile NIRvana Sciences is a tools development company founded to commercialize novel fluorescent red and near-infrared dyes. These molecules possess unique spectral properties that directly address the growing need for increasingly complex tests in life science diagnostics and imaging markets. NIRvana has been operating for five years, has 6 employees and is in the process of expanding into larger laboratory space. NIRvana has two short-term goals:

1) Collaborate with a small number of flow cytometry reagent companies

2) Be acquired by one of them who can integrate our dye platform into their global reagent platform.

Product and Technology Dyes used as reporter molecules in flow cytometry are rare because they must possess the proper combination of fluorescent, spectral and structural properties. Therefore, it has taken over 40 years to advance flow cytometry detection from two colors of dyes to approaching 25-30 novel colors. The ability to perform increasingly complex interrogation of the immune system by analyzing more dyes is a primary driver of advancements in the field. This need will only continue to grow as developers of drugs, vaccines and personalized cancer therapies continue to seek breakthroughs. Advances in the optics systems of flow cytometers has led to the recent launch of instruments that are capable of analyzing samples for 40-50 different types of reporter molecules (dyes). However, the actual performance capability of advanced flow cytometers is half of their potential capability due to a lack of available new dyes. Leading companies are now focusing on narrow emission and near-infrared emitting dyes so they can extract more and more information from every sample. NIRvana Sciences has dyes with ultra-narrow emissions that can fill this need for more multiplexing NIRvana Sciences is developing a portfolio of 12-14 dyes to meet the performance requirements for flow cytometry reporter molecules. Most of these will be new-to-the-world colors that will increase flow cytometer performance, particularly in the newly emerging detection range from 800 nm-1,100 nm. NIRvana has been focused on water solubility and linker chemistries and is very close to product commercialization. NIRvana has exclusively licensed world-wide rights to 20+ issued patents to all fields.

Market Potential The flow cytometry market including reagents, instrumentation, software, and services is projected to grow to $6.3 billion by 2020. That same year, the flow cytometry reagent market will reach $2.6 billion with the dye subsegment representing $497 million of this with an 11% annual growth rate. Our entry market customers include companies that supply reagents to research and clinical flow cytometry markets. Beyond flow cytometry, there are several other expansion market opportunities including cell imaging, and small animal (and eventually human) in-vivo imaging with particular emphasis on photoacoustic modalities.

34

Management Team Rich West, Chairman BoD, successfully exited Advanced Liquid Logic and is currently CEO of Baebies, a newborn screening and pediatric screening company in Durham, NC Wayne Brinster, BoD Director, is CEO of MedTest, a marketer of clinical diagnostic products. Formerly, he was CEO of Wheaton Industries and held senior positions at Becton Dickinson. Lisa Cooper, BoD Director, is a co-founder of PMI Ash Technologies, which was a clean-tech spin-out from a major utility company. Russell Thomas, BoD Director and CEO Bruce Pitner, CSO, NIRvana Sciences. Prior to joining NIRvana, Bruce was a senior scientist at Becton Dickinson Technologies where he spent 20+ years predominantly working on fluorescent dye-related research and product development. Petra Weishaupt-Smith, CFO, NIRvana Sciences. Petra has extensive experience in early stage life science companies that are involved in raising equity, corporate development and licensing agreements, and federal grants.

Financial Forecasts NIRvana Sciences expects to be a strategic technology acquisition.

35

OncoSpherix, Inc. (Early Stage) 7935 Fawndale Way Atlanta, Ga 30350 Phone: (770) 905-5369 www.oncospherix.com offermann@oncospherix.com

Presenter Margaret K. Offermann, M.D., Ph.D., President and CEO, is a founding partner of the Salutramed Group where she has been working with pharmaceutical and biotechnology company CEOs on business and scientific strategies and has been involved in the formation several new biopharmaceutic companies. She is past President of the Federation of American Societies for Experimental Biology (FASEB), past Founding Medical Director of the Mission Healthcare Cancer Center in Asheville, NC, past Deputy National Vice President for Research at the American Cancer Society, and past Professor of Hematology and Oncology at Emory University. She is a board certified medical oncologist who trained in Internal Medicine at the University of Chicago Hospitals and in Medical Oncology at Dana Farber Cancer Institute, an affiliate of Harvard Medical School.

Company Profile diversified and risk-mitigated proprietary platform of small molecule therapeutics designed to treat cancers displaying regions of hypoxia, where tumor cells are starved for oxygen. The platform consists of lead and follow-up compounds that inhibit the activity of hypoxia-inducible factor (HIF) transcription factors through a novel mechanism. HIF inhibition deprives tumors of new blood vessels and blocks the expression of genes that contribute to tumor survival and spread under oxygen-deprived conditions.

Therapeutic efficacy has been demonstrated in multiple pre-clinical mouse models of solid tumors, both alone and in combination with cytotoxic chemotherapy. These models have demonstrated reduced tumor burden and prolongation of survival.

OncoSpherix is preparing for IND-enabling studies of its lead compound. The Company plans to test its lead compound in combination with other drugs for the treatment of advanced solid cancers. The National Cancer Institute Development Therapeutics Program is currently executing some IND-enabling studies at no charge to OncoSpherix. The Company anticipates filing an IND for the lead compound within 18 months.

Near-term clinical development will focus on improving tumor control and survival in patients with unresectable advanced cancers by combining the lead compound with current standard of care chemotherapy, including targeted small molecule therapy, immunotherapy, and/or radiation, so that both hypoxic and oxygenated regions of advanced cancers are aggressively targeted simultaneously. The ability to attack tumors in this way fits within well-understood and broadly accepted paradigms for cancer management.

OncoSpherix founding leadership team has deep experience in tumor biology, medicinal chemistry, oncology, drug development, clinical trials, company management, fundraising and value creation.

Product and Technology OncoSpherix’s proprietary small molecule therapeutics work where most other treatments fail: in poorly oxygenated areas of unresectable cancers. Lead compounds block hypoxia-inducible factor-1 (HIF-1) induced gene expression, thereby blocking angiogenic factor VEGF production and expression of proteins that contribute to tumor survival and metastasis (e.g., c-Met and CXCR-4). The lead compounds also block vascular cell responses to VEGF and fibroblast growth factor. Follow-up compounds have additional functionality that includes inhibition of mitochondrial Complex 1, thereby targeting cancers that rely on oxidative metabolism for survival. All compounds have sufficient lipophilicity and small size (<500 Da) to improve cell membrane penetration and biodistribution compared to protein-based inhibitors of VEGF (anti-VEGF antibodies or soluble VEGF receptors). In addition, the production of OncoSpherix compounds is much simpler, with lower cost of production than protein-based inhibitors of VEGF.

36

Market Potential The market for OncoSpherix drugs is vast. It includes most of the > 600,000 cancer patients who die from unresectable solid tumors in the US each year. We anticipate capturing much of the market for cancers that are currently treated with the VEGF inhibitors bevacizumab and aflibercept, agents that currently generate over $10 billion in revenues annually.

OncoSpherix’s lead compounds block production and responses to VEGF with superior biodistribution properties and lower cost to produce. They also block expression of additional hypoxia-induced genes that contribute to tumor invasion and metastasis (e.g., CXCR4 and c-Met). These characteristics are anticipated to provide superior efficacy. OncoSpherix compounds are well tolerated and are designed to be used in combination with other agents. They complement rather than compete with the growing list of approved therapies and offer opportunities for strategic relationships through partnerships with other companies producing complementary therapies.

Management Team Margaret K. Offermann, M.D., Ph.D., President and CEO. As Founder and a Managing Partner of The Salutramed Group, she has been working with CEOs of early stage companies on business and scientific strategies. She has advised multiple public and private companies on fundamental issues that resulted in the strengthening of corporate value, including building appropriate teams, addressing scientific and technical challenges, competitive positioning, regulatory requirements, risk mitigation, and corporate governance. She is a board-certified medical oncologist and widely published biomedical researcher. She has served as chief medical officer for two start-up companies and as founding medical director of the Mission Health System Cancer Center in Asheville, NC. She served as past President for the Federation of American Societies for Experimental Biology (FASEB) and as Deputy National Vice President for Research at the American Cancer Society (ACS). She is also former Professor of Hematology and Oncology at Emory University.

Erwin Van Meir, Ph.D., Chief Scientific Officer. The fundamental research that led to the identification of the proprietary OncoSpherix drugs originated in the laboratories of Dr. Erwin Van Meir at Emory University and Dr. Binghe Wang (another founder of OncoSpherix and a renowned medicinal chemist) of Georgia State University. Dr. Van Meir has spearheaded the studies demonstrating efficacy and mechanism of action. Dr. Van Meir is Professor of Neurosurgery and Hematology & Medical Oncology at Emory University. He is leader of the Cancer Cell Biology program at the Winship Cancer Institute and is an Endowed Winship Professor in Cancer Research. He has extensive expertise in molecular basis of tumorigenesis, experimental therapeutics and drug discovery. He is author of over 200 peer-reviewed scientific articles in translational oncology that are highly cited (H index of 79; >26,300 citations). He is a principal on four patents that OncoSpherix is licensing from Emory University, Scripps Research Institute and Georgia State University.

Financial Forecasts The initial drug discovery and development has been supported by over $7.5 million in NIH and private foundation grants to the laboratory of Dr. Erwin Van Meir at Emory University over the past 11 years. OncoSpherix is now seeking $5 million in financing to translate this academic work to the patient. These resources will enable it to build its management team, complete investigational new drug (IND) submission, launch its initial Phase 1 trial and advance its pipeline. OncoSpherix’s lead compound, 64B, is within 18 months of IND filing and start of a phase I clinical trial. Some of the IND-enabling studies are being executed at no charge to OncoSpherix, after the project was selected for the newly launched “Stepping Stone” program of the National Cancer Institute’s Developmental Therapeutics Program.

37

Panacea BioMatx, Inc. (dba) Panaceutics, Inc (Early Stage) 6 Davis Drive Research Triangle Park, NC 27709 T 919.797.9623 www.panaceutics.com

Presenter Edison T Hudson, CEO, Co-founder of the Company and designer of the technology platform to deliver personalized pharmaceuticals formulations on demand, each one customized to individual’s digital health profile using high throughput robotic compounding.

Company Profile (Sectors: Personalized Medicine/Adherence, Systems/Specialty, Pharmaceuticals/ Personalized Wellness / Personalized Nutrition) Panaceutics’ patented technologies solve the problem of delivering personalized therapies to large populations. In past 5 years, the Company has designed digital formulation software, developed proprietary chemistry, and built 2 generations of modularly scalable robotic compounding automation. The Company is poised to grow from a 2018 base of $10 M by utilizing its technical platform to enter several markets for personalized drug therapies for chronic diseases beginning with a major hospital system contract. Our research team’s development of several generic drug reformulations using our patent pending process has yielded laboratory data to support multiple FDA 505(b)(2) filings. A $5 Billion international pharmaceutical company has signed a contract with the Company to reformulate several of their branded generic drugs to be compatible with the Company’s personalization platform, bringing the potential to drive licensing and global business opportunities over the next five years.

Product and Technology The Company’s technology platform enables the high-speed manufacture of multi-drug therapies, with each drug accurately titrated at a customized dose. Such “poly-therapies” have been shown in clinical trials to bring significant improvements in adherence and health outcomes simply by reducing pill burden. Multiple international studies of this combinatorial approach showed a reduction of secondary heart attacks and strokes by up to 50% in one year. The Company has pioneered several pill-free delivery forms, using gel, puree or smoothie suspensions that stably combines multiple medications in a single convenient to use pouch serving. These shelf stable forms are especially beneficial for geriatric and pediatric formulations, being easy to swallow, and good tasting, improving adherence behavior through sensory appeal, and using consumer psychology, allowing patients to choose their flavor on each refill. The Company conducted national trials using its suspension product format to deliver up to 20 dietary supplements and nutraceuticals at once. Customers who used the product for two months favored this delivery format by 88% over traditional pill delivery. The key drugs to serve a coronary artery bypass patient population are completing stability testing and will be then be used in a 6-8 long week bioequivalence study with Florida Hospital’s Transition Research Institute. The Company has been issued multiple patents including US, EU, Canada, Australia, and New Zealand for its “Method and System for Making Customized Formulations for Individuals”. Seven additional patents have been filed. The Company’s processing technology is 10 to 100 times faster than alternative experimental technologies such as 3D printing or selective powder deposition.

Market Potential An agreement with Florida Hospital’s Cardiovascular Institute was signed to develop a combinatorial therapy to supply their population of 70,000 Cardio-Vascular Disease (‘CVD’) patients. This program will ultimately demonstrate the value of “precision generics” combinations, transforming low cost generic CVD drugs into more effective therapies with fewer adverse side effects and improved adherence. Several other hospital systems including the Adventis Healthcare Systems, have shown interest to follow the results of this CVD program. The addressable market size for CVD poly therapies is very substantial with US market exceeding $1.5 Billion a year at projected penetration rate of 2% and a daily cost/patient averaging $2.00. “Poly-pills” sold in the UK, EU, India, and Australia have confirmed reductions of over 40%-50% for secondary heart attacks and strokes, even though these early poly-pills cannot be adjusted to suit individual patients and are often large and hard to swallow. Integrated healthcare systems have told the Company that they believe the Panaceutics system will improve their Accountable Care Organization scores as well as a practical use of genomics to support personalized medicine in a competitive healthcare environment.

38

In a development contract with a $5B international branded pharmaceutical manufacturer, the first project is to create a formulation for widely prescribed hypothyroid treatment to replace a current product line of 12 pills with a single variably dosed form produced using the Panaceutics system. The Company’s technology platform has also been used to make personalized clinical and small batch consumer nutrition products. In a recent spin-off of its personalized nutrition business, a separately funded and managed joint venture LLC with DSM and other investors, has been created to support major B2B contracts including one with Abbott Nutrition and with other CPG partners. Panacea BioMatx owns 65% of this Panaceutics Nutrition LLC spin off. Our strategic nutrition partners believe that the market for personalized nutrition and wellness will grow to several $Billions over the next 5 years.

Management Team The Company integrates 37 professionals covering disciplines of software and robotics engineering alongside biochemists and five PharmD’s and many skilled technicians. The Company’s Advisory Board includes leading academics from Duke University Medical School, UNC Eshelman School of Pharmacy, NCSU’s Biotech (BTEC) faculty and senior healthcare industry executives. Edison Hudson, CEO, Co-Founder Entrepreneur with 4 exits, served on 2 IPO teams, 20+ patents in robotics and AI, senior director at iRobot, Duke University MBA, Graduate study at Oxford University, UK Lloyd Staton Noel, III, Chief Science Officer, Co-Founder Pharmacologist with 20 years drug development at GSK, expert in biotech IP and tech transfer at University of North Carolina, MS Gerontology, MBA Danny Barnes, PharmD, | Chief Pharmacy Officer President, operator of top accredited 503A pharmacies, built one of first 503B FDA Facilities Andrew Schwab, PhD, Chief Operating Officer Life sciences expert covering business development, financial, IP strategy, legal, Operations Ray Szafranski, Jr, CPA, CMA| VP Finance – Controller Experienced financial controller, at Tecan in laboratory automation, GSK, KPMG, Duke MBA Mark Montgomery | Senior Board Member and Advisor Specialty pharm executive, former CEO of Axium Healthcare ($2B revenue) sold to Kroger, and was Vice President at CVS/CareMark, Florida Hospital Cardiovascular Institute Board

Financial Forecasts Company revenue at September 30th, 2018 was over $10 M (TTM) from activities in specialty and compounding pharmacy, clinical trials, and development contracts. These projections are built on that history and existing contracts, with no licensing or royalty income included. The Company is seeking a minimum of $6 Million in a Series B offering, up to $12 Million including $3 M already raised as convertible notes from existing investors. Key uses of funds will be to accelerate the testing phase for the CVD poly-therapy, continue development of the software /hardware technology platform, FDA regulatory filings for some of the Company’s generic drug reformulations, and the addition of marketing and regulatory executives. The base pharmacy business is projected to be cashflow positive in early 2019, with the full company at cashflow positive as early at late 2020. Earlier breakeven is dependent on timing of the release of the cardiovascular product, with a close of the Series B by end of 2018 moving forward BE by up to 6 months. Management projects that enterprise exit valuation could be very positively impacted upon approval of any of its 505(b)(2) filings as early as Q4 2020.

Income Forecast 2019 2020 2021 2022 2023 Net Sales $11,812,051 $18,396,722 $31,742,121 $44,333,754 $74,052,648 COGS $7,716,827 $11,036,132 $16,945,474 $22,555,419 $35,236,519 Gross Profit $4,095,224 $7,360,590 $14,796,647 $21,778,335 $38,816,129

Sales & Marketing $285,636 $751,337 $1,691,314 $2,550,408 $4,730,819 RX R&D/FDA Filings $1,026,132 $1,283,860 $1,399,699 $1,511,711 $1,727,396 Operating Expenses $3,117,822 $4,913,985 $7,038,517 $9,154,959 $11,992,735

EBITDA ($334,366) $411,408 $4,667,118 $8,561,257 $20,365,179

39

RFPi, LLC (Early Stage) 1800 N. Greene Street, Suite K Greenville, NC 27834 Phone: (919) 280-2953 www.rfpi-co.com jeff.basham@rfpi-co.com

Presenter Jeffery Basham, CEO, and successful serial entrepreneur. He was the founding CEO of the company that became Closure Medical, which developed the first successful synthetic wound closure glue.

Company Profile RFPi, Inc. (“RFPI” or the “Company”) is bringing to market a technology that will provide doctors the ability to see what in the past they could not; the distribution of blood flow in tissues and vessels. This technology has the potential to disrupt key surgical, wound management and noninvasive medical imaging markets. The Company submitted a 510k application in May 2018 for an open surgical device (iCertaintyTM) and expects approval by the end of the year.

RFPi’s technology was developed at East Carolina University (ECU) through a partnership between Dr. Bruce Ferguson, a renowned cardiac surgeon, and Dr. Cheng Chen, an expert in imaging and optical physics. From the beginning of their collaboration in 2008, they have developed and tested the iCertainty technology. The founders started RFPi with seed funding in 2014, brought on professional management, and began working on the commercialization of the technology. RFPi has licensed the technology from ECU and is expanding the intellectual property base through further research and development. The company plans to commercialize the technology starting in 2019 in hospital operating rooms in the United States. Future expansion includes the application of the technology in other areas, such as wound clinics, and in other geographies.

RFPi is also seeking industry partners to facilitate and/or accelerate these long-term expansion areas. The company has already secured a partner for Japan. In 2017, RFPi signed an investment and license agreement with Nipro Corporation for the Japanese market and intends to launch there in early 2020.

Product and Technology The technology is Multi-Spectral Physiologic Visualization (MSPV). MSPV combines hardware with software to visualize (‘see’) blood flow in vessels and perfusion in organs and tissues in real time. The technology uses lasers, a high-speed camera, and a proprietary combination of laser imaging flow calculation algorithms and analysis techniques to bring this visualization of physiology to the user.

The technology is unique in that it needs no injection of material, no probes and never touches the patient. RFPi’s device will enable surgeons to adjust their surgical approach and decision making, significantly reducing procedural complications and surgical readmissions.

RFPi intends to bring its benefit to hospitals and health systems by: 1) improving the quality of care for surgical patients; 2) reducing the cost of complications including repeat surgeries, 3) maximizing quality-based reimbursement, and 4) reducing quality-based Medicare and Medicaid penalties.

RFPi envisions capture of the imaging, clinical and financial outcomes data from the procedures to further improve healthcare outcomes. RFPi has a partnered with ARMUS Corporation (San Mateo, CA) for data capture into a proprietary HIPAA-compliant database system designed and hosted by ARMUS. Health care providers and administrators can use these analyses to track and improve surgical outcomes, thereby reducing cost.

Market Potential Market size: With the company’s focus on the surgical suite, RFPi expects to focus initially on key procedures where blood flow and perfusion are critical to surgical success: GI surgery, vascular surgery, breast reconstruction.

40

Based on the 4,700 hospitals and 1,800 wound care centers in the United States, RFPi calculates the US market opportunity at $800 million and estimates a worldwide market of $2.4 billion.

Competition: The competition for these products will include the various types of ‘real-time’ imaging (i.e., Novadaq, CW Optics, Moor Technologies) or flow measurement (i.e., Medistim) technologies. All of these are invasive (require an injection and/or direct contact with tissue), all substantially interrupt the flow of the surgical procedure in order to obtain and then analyze the imaging data, and all are without true real-time application and analysis. Surgeons can utilize the iCertainty device in the operating room as an integrated part of the surgical procedure. This removes a significant roadblock that has hampered the adoption of other imaging techniques in the operating room.

Customers: Hospitals are the target customers to purchase iCertainty. Hospitals must consider both the clinical benefit and the financial impact of a medical device considered for adoption. Capital budget acquisition decisions are made by value analysis technology committees, including administrative, finance and physician representation. Recent trends in the marketplace include the rise of hospital buying groups, which act on behalf of multiple hospitals.

Marketing channels: RFPi is targeting the hospital market, which is the primary location for open surgeries, and expects to obtain market share from key large hospitals. RFPi will aim to make iCertainty the “standard of care” for open surgeries in these hospitals. To accomplish that, RFPi will be establishing economic clinical outcome data through surgeons who are Key Opinion Leaders. There are 4,700 US hospitals that perform over 800 thousand of these open surgical procedures annually. RFPi will utilize direct sales representatives to target large hospitals and hospital buying groups first.

Market penetration: RFPi is targeting achieving 20% market penetration within 5 years. The iCertainty technology provides clinical and financial benefits to hospitals and doctors, and has notable advantages over the competition (ease of use, non-invasive, lack of interruption, image quality, etc.).

Management Team Jeffery Basham, MBA, CEO and successful serial entrepreneur. He was the founding CEO that became Closure Medical, which developed the first successful synthetic wound closure glue. Closure medical was eventually sold to J&J for $500 million. Peter Geiger, MBA, CFO is a graduate of the Wharton School and a former divisional CFO for a pharmaceutical manufacturer. Bruce Ferguson, MD, Chief Medical Officer is a renowned cardiac surgeon with extensive experience in utilizing imaging in the surgical setting. He is the former Chairman of the Department of Cardiovascular Sciences in the Brody School of Medicine at ECU. Cheng Chen, Ph.D., Chief Technology Officer is an expert in imaging with PhD in optical physics. Dr. Chen has developed the imaging technology and software algorithms used in RFPi’s technology.

Financial Forecasts

RFPi is currently raising $8 million in a convertible note / Series B round. The funds will be used for the commercialization of its first product.

2019 2020 2021 2022 2023

Revenue 1,780 18,077 39,875 105,425 197,387

Expenses 6,193 12,009 27,084 68,091 126,058

Net result (4,413) 6,067 12,791 37,334 71,329

41

STAT3 Therapeutics (Early Stage) 5645 Coral Ridge Drive Suite #275 Coral Springs, FL 33076 www.STAT3Therapeutics.com info@stat3therapeutics.com

Presenter(s) Matthew H.J. Kim, JD, co-founder, is an accomplished leader and serial entrepreneur bringing more than 20 years of experience encompassing business and corporate development, intellectual property monetization, and commercialization of various product launches to his leadership role at STAT3 Therapeutics. Prior to founding STAT3 Therapeutics, Matthew successfully founded Vigilant Biosciences, a company that develops solutions that aid in the early detection and intervention of head and neck cancer based on personal inspiration. Matthew was instrumental in Vigilant’s corporate development and financing efforts including raising $20MM in both investor and grant funding to advance technology exclusively licensed from the University of Miami from concept to commercialization. Before Vigilant Biosciences, Matthew was involved in the founding of several start-ups, including a lung disease-focused specialty pharmaceutical spin-off from the Centers for Disease Control and Prevention (CDC). Matthew received his undergraduate degree from Washington University in St. Louis and his law degree from Georgia State University. He is also admitted to practice before the U.S. Patent and Trademark Office. His and his companies’ honors and recognitions include BioFlorida’s Entrepreneur of the Year, BioFlorida BioPitch winner, AUTM Venture Forum Life Science Startup of the Year, and SEMDA Company Spotlight Award.

Christine Neipert, PhD, co-founder, is a passionate entrepreneur in the healthcare space. Prior to joining STAT3 Therapeutics, she co-founded a healthcare delivery practice and served as its director of operations for 5 years. Dr. Neipert has worked as a consultant for Baird Capital to assist with investment target diligence as well as served as the operations and intellectual property (IP) director for a renal therapeutics start-up company. Prior to this experience, Dr. Neipert was an IP licensing manager at the University of Miami, and an in-house IP technical specialist for private industry. Dr. Neipert received her Ph.D. in Chemistry from USF and is a registered US Patent Agent.

Company Profile Founded in late 2017, STAT3 Therapeutics (S3T) is a pre-clinical biopharmaceutical and oncology-focused company engaged in the development of novel therapeutics that block STAT3 activity, a transcription factor that negatively influences anti-tumor activity and is associated with poor survival in ~70% of cancers. S3T is currently raising financing to complete its IND-enabling preclinical program.

Product and Technology 1st-in-class STAT3 decoy comprising of a patented double stranded DNA sequence that mimics the genome docking site

for the activated STAT3 protein dimer and thereby inhibiting its function by preventing its attachment to its target

cancer genes for activation. This decoy is readily taken up by cells, inhibits target genes expression, and produces

robust anti-tumor activity with favorable toxicology profile. This novel approach overcomes legacy challenges of the

competition targeting other aspects of the STAT3 pathway which has resulted in limited clinical advancement. Proof-

of-concept for S3T’s STAT3 decoy has been established with multiple solid tumors in both human and animal models.

42

Market Potential The STAT3 decoy has the potential to be leveraged in multi-billion dollar markets similar to Keytruda/Opdivo as a

multiple indication single asset opportunity. STAT3 Therapeutics lead indication is in head and neck squamous cell

carcinoma (HNSCC). There is a critical need for new therapeutic approaches to manage HNSCC with better anti-tumor

activities and toxicity profiles. 95% of HNSCC overexpress STAT3. HNSCC is the sixth most common cancer worldwide

with >500,000 cases diagnosed each year. HNSCC patients often present with advanced disease and are managed with a

multi-disciplinary approach consisting of surgery, chemotherapy, and/or radiation. Follow on indications include non-

small cell lung cancer, glioblastoma, and skin cancer.

Management Team Matthew H.J. Kim, JD, Corporate Development & Finance – (please see presenter profile) Christine Neipert, PhD, Intellectual Property & Strategic Alliances – (please see presenter profile)

David Johnson, PhD, Product Development (and co-founder), is a senior pharmaceutical executive with extensive experience in preclinical and clinical drug development, regulatory affairs and product commercialization. Over the last 10 years he has conducted a thriving consultancy and interim executive management business supporting a variety of companies in strategic and cost effective drug development. From 2004 through 2007 he was Senior Vice President of Research and Development for Nektar Therapeutics and Chairman of Nektar India, where his responsibilities included planning and operations for drug delivery, including inhalation technologies, pegylation technology, clinical development, regulatory affairs and safety, quality control and assurance for clinical supplies, and product and device development. Prior to Nektar, he was Chief Development Officer and Vice President Operations for Control Delivery Systems where Dr. Johnston oversaw co-development of the Retisert™ product, marketed by Bausch and Lomb for the treatment of uveitis. He has previously held executive leadership positions with AAI International and Oread, Inc., both contract research organizations providing product development and support services for pharmaceuticals, biologics and medical devices. Dr. Johnston earned his bachelor’s and doctorate degrees in chemistry from St. Andrews University and completed postdoctoral training at the Max Planck Institute for Medicinal research.

Jennifer R. Grandis, MD, Scientific Founder, is a Professor in the Department of Otolaryngology – Head and Neck Surgery (OHNS), and she is the Associate Vice Chancellor—Clinical and Translational Research (AVC-CTR) at the University of California, San Francisco. She received her medical degree from the University of Pittsburgh School of Medicine, Pennsylvania, and she completed her internship from the same institution. Prior to joining UCSF, Dr. Grandis was the Endowed Chair in Head and Neck Cancer Surgical Research and Distinguished Professor of Otolaryngology and Pharmacology and Chemical Biology at the University of Pittsburgh. She led the Head and Neck Cancer Program and was the Vice Chair for Research in the Department of Otolaryngology. Dr. Grandis’s research focuses on the signal transduction in head and neck squamous cell carcinoma (HNSCC) development and progression with the ultimate goal of targeting key pathways for therapeutic benefit. Dr. Grandis is an American Cancer Society Clinical Research Professor, and a member of the American Society for Clinical Investigation, the American Association of Physicians and the Institute of Medicine of the National Academies. She has published over 260 peer-reviewed articles and also contributed to more than 50 review articles and book chapters.

Daniel Johnson, PhD, Scientific Co-Founder, is a Professor in the Department of Otolaryngology – Head and Neck Surgery (OHNS) at the University of California, San Francisco. He obtained a bachelor of science in chemistry and a bachelor of arts in mathematics, both from North Park University in Chicago, Illinois. Dr. Johnson earned his MA and PhD in molecular biology from Princeton University, followed by a postdoctoral fellowship at the University of California, San Francisco. Prior to joining UCSF Otolaryngology, Dr. Johnson was a Professor in the Division of Hematology/Oncology, Department of Medicine, and Department of Pharmacology and Chemical Biology at the University of Pittsburgh, Pennsylvania. Dr. Johnson has published 68 original papers and 21 reviews and book chapters, and is Editor for the book entitled “Cell Death Signaling in Cancer Biology and Treatment”. Since 2001 he has served as a Section Editor for Leukemia, the top-ranked journal for hematologic malignancies, and has also served as Editor for Cancer Research and Oncology Research.

43

Symberix, Inc. (Early Stage) 4819 Emperor Blvd, Suite 400 Durham, NC 27703 Phone: (919) 522-1906 www.symberix.com Ward.Peterson@Symberix.com

Presenter Ward Peterson, PhD, Chairman & CEO, is co-founder of Symberix. He brings 20 years of experience in discovery and development of new chemical and biological entities from early drug discovery to late-stage clinical trials. Dr. Peterson held scientific and executive positions at Regeneron Pharmaceuticals and Inspire Pharmaceutics from 1998 to 2011, and since then has provided executive consulting services to various life-science organizations including Croma Pharma as CSO, GrayBug Vision as Senior VP, Liquidia, Neurotech, Ono Pharma, and Hatteras Venture Partners. He led the scientific team at Inspire Pharmaceuticals as SVP of Research and Preclinical Development/Scientific Affairs. While serving on the Executive Team at Inspire, Dr. Peterson participated in fundraising substantial equity capital prior to the acquisition of the company by Merck & Co. in 2011. He earned his BA in Physics from Pomona College and PhD in Biophysics from University of California, Berkeley. He is a co-inventor on 15 issued patents.

Company Profile Symberix, an early-stage spin-out of the University of North Carolina at Chapel Hill, is pioneering the first generation of microbiome-targeted, small-molecule drugs to improve human health by selectively eliminating harmful microbial activity in the gut without killing beneficial microbes. Symberix’ scientific founder, Matthew Redinbo, PhD, was the first to demonstrate the feasibility of therapeutically targeting the microbiome with symbiotic drugs. Based on this breakthrough research, the company is advancing a first-in-class approach that could meaningfully improve the treatment of serious lower gastrointestinal (GI) diseases as well as mitigate the debilitating lower GI side effects associated with various cancer, pain and immunosuppressive therapies. Symberix’ internal team and scientific/clinical/business advisors have a deep understanding of the biology of the microbiome as well as extensive drug discovery, clinical development and commercial biopharma experience. Symberix’ vision is to deliver safe and effective pharmaceutical control of the microbiome.

Product and Technology The healthy gut microbiota is composed of a diverse and balanced population of tens of trillions of predominantly commensal and symbiotic microbes whose actions contribute to our well-being. Microbiota dysbiosis, an imbalance in the composition of commensal/symbiotic vs pathogenic microbes, has been shown to cause or otherwise correlate with many human ailments and diseases. Symberix’s initial microbiome target is the beta-glucuronidase enzyme (GUS) expressed in E. coli. Preclinical studies conducted by Dr. Redinbo and Symberix show that a small-molecule inhibitor of E. coli GUS ameliorated serious chemotherapy-induced lower GI side effects; protected the small intestine from NSAID-induced enteropathies including intestinal ulcer, inflammation and bleeding; and reduced anastomotic leak associated with NSAID use following GI surgery. The human gut microbiome comprises nearly 300 distinct GUS enzymes (the GUSome platform) and Symberix is developing novel GUS inhibitors as symbiotic drugs for use as adjunctive therapy to improve the therapeutic window of existing FDA-approved drugs, or as monotherapy for various serious lower GI disorders. Symberix has developed two libraries of novel, potent, and bacteria-selective compounds with potential NCE patent coverage as well as various broad method-of-use patent claims. The company has access to a platform of druggable targets expressed in the human gut microbiome and has developed novel and broadly useful assays to facilitate microbiome-targeted drug discovery. The company anticipates initiating IND-enabling preclinical studies of its lead compounds in 2019 and clinical development the following year.

Market Potential Initial applications of the Symberix approach:

1) Monotherapy treatments for lower GI diseases such as Inflammatory Bowel Disease, a group of inflammatory conditions of the colon and small intestine including Crohn's disease and ulcerative colitis. This is a total addressable market of an estimated 1.3% of US adults, or 3 million patients each year, according to the Centers for Disease Control.

44

2) Therapeutic adjunctive products to mitigate the debilitating lower GI side effects associated with various effective cancer and pain products. These could become as meaningful to patients, and potentially as commercially successful, as those developed for drug-induced upper GI side effects, such as vomiting, nausea, and gastric ulcer.

a. Cancer: The annual incidence of cancer patients in the US is 1.7 million and prevalence is 15 million (ACS). From CDC and other reports, it is estimated that more than 1 million cancer patients receive chemotherapy each year. Symberix estimates that up to one-half million patients treated with targeted cancer agents or chemotherapy that produces lower GI side effects would be candidates for Symberix’ approach each year.

Management Team Ward Peterson, PhD, Chairman & CEO (see bio above) Matthew Redinbo, PhD, Chief Scientific Officer, is co-founder of Symberix and Kenan Distinguished Professor at University of North Carolina at Chapel Hill in the Departments of Chemistry, Biochemistry & Biophysics, and Microbiology & Immunology. He was Chair of UNC’s Chemistry Department from 2009-2012. He has authored more than 100 publications based on original research and has been invited by the FDA to discuss the scientific and regulatory aspects of microbiome-targeted therapeutic interventions. Dr. Redinbo earned his BS in Biochemistry and English from University of California Davis and PhD in Biochemistry from University of California Los Angeles. Gregory J. Mossinghoff, Chief Business Officer, has over 25 years of domestic and international bio-pharmaceutical industry experience. Starting with a 10-year big-pharma foundation at Roche and Glaxo, he has subsequent experience in numerous emerging bio-pharmaceutical companies in various roles such as Board Member, President, CEO, CBO, CFO, Principal Financial Officer and Co-Founder. He has co-led multiple venture financing rounds and two successful biotech IPOs: G1 Therapeutics, with a current market capitalization of over $1.5b; and Inspire Pharmaceuticals, which was subsequently acquired by Merck & Co. In total he has participated in raising more than $450m in public and private equity capital and has negotiated and closed more than twenty important licensing/partnership agreements. Mr. Mossinghoff has a BA in Economics from the University of Virginia and an MBA in Financial Management and Analysis from George Mason University.

Financial Forecasts Up to one-third of all patients treated with targeted cancer products, chemotherapy agents, and non-steroidal anti-inflammatory pain drugs experience lower GI side effects. These can result in dose-reduction and/or discontinuation of otherwise effective treatments. If successful, the Symberix approach could help millions of patients in the US alone and result in blockbuster commercial product opportunities. The company is seeking Series A venture capital funding of approximately $15m to $20m in 2019. Product revenue is expected to be generated approximately six years after funding with profitability beginning several years after that.

45

Symmune Therapeutics (Early Stage) 201 West Main Street, B026 Durham, NC 27701 Phone: (650) 823-1706 www.symmune.com jesse.keicher@symmune.com

Presenter Jesse Keicher, President and Founder Twenty years industry experience Biochemistry, BS; Chemistry, MS Michael M. Conger, IP Legal and Business Development Practicing IP Law, five years private practice and fifteen years at GlaxoSmithKline (GSK). Biology, B.S.; Law, J.D.

Company Profile Symmune Therapeutics is a pre-clinical virtual biotechnology company formed in 2015. Symmune Therapeutics consists of two core members including, Jesse Keicher, President and Founder and Michael Conger, IP Legal and Business Development. The rest of the team is made up of advisors and consultants. Near-term company goals consist of completing all remaining IND enabling studies for our lead product SYM-001 over the next 12 months and submitting an IND. The long-term company goal is the clinical development of SYM-001 in order to meet the development stages associated with significant value inflections. The first inflection point follows phase IIa, the completion of a human rhinovirus challenge study in healthy adults and subjects with COPD. Completion of the study is planned for Q1 2021 and will require $20 million in total aggregate development costs. The second inflection point follows phase IIb, the completion of a 3-months field study of SYM-001 in frequently exacerbating subjects with COPD during the cold and flu season. Completion of the study is planned for Q1 2022 and will require $40 million in total aggregate development costs.

Products and Technology SYM-001 is a proprietary composition of non-toxic polysaccharides which act as PAMPs and are recognized by PRRs on innate immune cells. SYM-001 was specifically designed to attenuate the inflammation that is associated with respiratory viral infections and is the primary cause of acute COPD exacerbations. Through epigenetics and chromatin remodeling, SYM-001 restores effective innate immune cell responses and attenuates secondary inflammation (excessive production of cytokines/chemokines) in response to respiratory viral infections in patients with COPD. SYM-001 is a once or twice weekly nasal spray being developed as an add-on to standard of care for the management of virally-induced acute exacerbations. SYM-001 is currently a preclinical asset and provisional patents covering the composition and methods of treatment are being filed. Excessive inflammation has been shown to be the primary driver of morbidity and mortality in mice challenged with H1N1 or H3N2 strains of the influenza virus. Treatment with SYM-001 prior to a lethal H1N1 or H3N2 influenza challenge attenuated the severe pathology normally associated with these viruses in mice. SYM-001 treatment:

• Confers 100% survival in SYM-001 treated mice compared to 0% in the untreated controls

• Attenuates virally-induced pro-inflammatory cytokines, the primary cause of acute exacerbations

• Reduces excessive lung neutrophil recruitment

• Improves viral clearance Reduces clinical pathology as demonstrated by reduced weight loss

Market Potential Among the twelve million physician-diagnosed COPD patients in the U.S., six million are actively managed by a health care professional. Of these actively managed COPD patients, about one million are considered “frequent exacerbators” who also represent our initial target market. Frequent exacerbators represent a distinct subpopulation of COPD patients that experience two or more acute exacerbations annually. Persons with the frequent exacerbator phenotype are prone to exacerbations as a result of intrinsic susceptibility and have

46

exacerbations on exposure to particular triggers, such as respiratory viral infection. The frequent exacerbator phenotype is a relatively stable phenotype which is easily identified from health records. This subgroup of COPD patients represents the greatest unmet medical need among patients with COPD. They are most likely to be admitted to the hospital, to demonstrate accelerated lung function (FEV1) decline and disease progression, and to have the highest all-cause mortality rates. On a per-patient level, the direct cost of health care that is associated with frequent exacerbators is twice that of non-frequent exacerbators, primarily the result of hospital admissions (Patel et al., Int J Chron Obstruct Pulmon Dis. 2018;13:2301–2311). The current standard of care anti-inflammatories consists of inhaled corticosteroids (ICS), macrolides, and PDE-4 inhibitors. These anti-inflammatory drugs however have severe limitations. The efficacy of ICS in COPD is highly debated, and ICS have a number of unwanted side-effects including, immunosuppression. They also increase the risk of pneumonia. Similarly, the use of macrolides is restricted due to fears of resistance. The use of PDE-4 inhibitors has serious side effects and is limited to patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

Management and Founders Jesse Keicher, MS, president and founder of Symmune Therapeutics. Mr. Keicher is the inventor of SYM-001 and has 20 years industrial experience. He is an expert in drug discovery, pre-clinical drug development, and is an inventor on numerous patents.

Michael M. Conger, J.D., IP Legal and Business Development, is a pharma IP attorney with five years in private practice and fifteen years at GlaxoSmithKline (GSK).

Financial Forecasts Symmune is seeking $20M to support the development of SYM-001 through the completion of Phase IIa, a human rhinovirus challenge study in both healthy adults and in patients with COPD, which represents our initial valuation inflection.

Symmune forecasts peak SYM-001 US COPD sales of $2.6 billion by 2028, capturing 40% of the frequent exacerbators (458,773) growing at an annual rate of 4.8% (Kim et al. BMC Pulm Med. 2013;13:35; Khakban et al. Am J Respir Crit Care Med 2017;193(3):287-291). SYM-001 nasal spray will benefit from the very high compliance rates (80%) associated with inhalation medications in the COPD patient population (Antoniu et al., Expert Review of Pharmacoeconomics & Outcomes Research 2010;10(2):115-117; Vestbo J et al., Thorax 2009;64:939–943). Initial SYM-001 pricing assumption of $650/month is at/below the specialty price threshold, enabling relatively wide payer acceptance

47

Tellus Therapeutics, Inc. (Early Stage) 517 Summit Trail Drive Hillsborough, NC 27278 Phone: (919) 491-4995 jasonkralic@tellustherapeutics.com ericbenner@tellustherapeutics.com

Presenter(s) Eric Benner, M.D. Ph.D., CSO, is the scientific co-founder of Tellus and an attending neonatologist at Duke University. He earned his MD and PhD in neuroscience from the University of Nebraska Medical Center before completing his pediatric residency at the University of North Carolina at Chapel Hill and a neonatal perinatal medicine fellowship at Duke University. He has over 10 years of experience caring for neonates with brain injury. Eric’s laboratory made the novel discovery that oxysterols present in human maternal breast milk promote oligodendrocyte (myelinating cells) differentiation in postnatal neural stem cells. Using animal models of perinatal white matter injury, his lab has shown that these compounds can reverse white matter injury and associated motor deficits. Eric has a personal connection to premature infants that drives his desire to improve the lives of these affected children. His own twin boys were born 3 months early.

Jason Kralic, Ph.D., President & CEO, is co-founder of Tellus, a neuropharmacologist and life sciences business development executive with broad experience in technology innovation, CNS R&D, company creation and licensing. Most recently, Jason was Associate VP of Technology Innovation at Wake Forest Baptist Medical Center, VP of Business Development at Opexa Therapeutics and Head of Neurosciences Business Development at GlaxoSmithKline responsible for setting the BD strategy, leading licensing and M&A activities and facilitating relationships with alliance partners. Jason has also served in scientific licensing roles at UCB Pharma and Schwarz Biosciences and founded Innervate BD Solutions, a CNS technology and business advisory firm in 2015. Jason holds a Ph.D. in pharmacology from the University of North Carolina at Chapel Hill and completed post-doctoral training at the University of Zurich.

Company Profile Tellus is a mission-driven company dedicated to developing a safe and effective treatment for brain injury in newborns. Founded in 2018, Tellus is translating breakthrough science from Duke University that identified compounds in breast milk that induce regeneration of myelin-producing oligodendrocytes and reverse white matter injury in an animal model of perinatal brain injury. As a preclinical stage life sciences start-up company, we are focused on planning, funding and executing a development program to enable evaluation of safety and efficacy in brain-injured newborns. Tellus aims to leverage institutional support, non-dilutive funding, equity investment and patient advocacy to de-risk the program and license to a biopharmaceutical company to complete development and maximize patient access. Our goal is a treatment for every baby born at risk for brain injury and improved neurodevelopmental outcomes for affected children.

Product and Technology One in ten babies is born preterm and at significant risk for brain injury and life-long cognitive and neurological impairments, such as cerebral palsy. Perinatal diffuse white matter injury (DWMI) is the leading cause of neurodevelopmental disability in survivors of preterm birth. There are currently no treatment options available. Tellus is developing an oxysterol found in human maternal breast milk that promotes oligodendrocyte differentiation in postnatal neural stem cell populations. Systemic administration of the breast milk-associated oxysterol rescued perinatal DWMI and reversed motor deficits in mice. Tellus’ lead candidate is in late preclinical development having initiated drug product formulation, IND-enabling work and preparation for a pre-IND meeting in 2019.

Tellus is uniquely positioned to develop the first treatment for newborns with DWMI. The mechanism of action is reparative and independent of the cause of white matter injury thereby providing an advantage over neuroprotective approaches that target only injury prevention. The exposure of breast-fed newborns to naturally-occurring oxysterols supports development as a therapeutic for neonates in which safety is paramount. Duke University and Tellus’ scientific founder have filed and maintained company-relevant patents protecting using of oxysterols for treatment of brain injury.

48

Market Potential Tellus' technology platform has potential to address a spectrum of unmet needs and market sizes from niche/rare diseases to prophylaxis in babies born at risk of brain injury as well as large and established markets for myelin injury, e.g., multiple sclerosis, stroke and traumatic brain injury. As the mission of Tellus is to develop the first treatment for DWMI in newborns, initial clinical proof of concept will be pursued in extremely low birthweight (ELBW) preterm babies (<1,000 grams at birth). ELBW preterm babies are at highest risk for injury and poor neurodevelopmental outcomes, of whom 50% will develop sepsis, necrotizing enterocolitis or sudden bowel perforation. Initial clinical proof of concept will support development in additional rare diseases, such as hypoxic-ischemic encephalopathy (HIE) and bronchopulmonary dysplasia (BPD), as well as for prophylactic treatment of all preterm and term babies at risk for brain injury.

Tellus’ customers are newborns in the neonatal intensive care unit (NICU). In addition to neonatologists, families of brain-injured newborns and patient advocacy groups (Cerebral Palsy Alliance, March of Dimes) are vocal proponents for the development and use of new treatments. Preliminary feedback from key opinion leaders supports patient treatment access and pricing/reimbursement due to lack of treatment options. Licensing to a biopharmaceutical company will enable market access through development of a data package that shows improvement in patient outcomes and reduction in healthcare costs, e.g., lesser incidence and severity of cerebral palsy and other cognitive and neurological deficits occurring after DWMI.

Management Team Eric Benner, M.D./Ph.D., CSO and scientific co-founder (see Presenters)

Jason Kralic, Ph.D., President, CEO and co-founder (see Presenters)

Alexander Ruckdaeschel, Board Member fhas significant experience in startup financing and operations. Co-founded Herakles Capital Management, AMK Capital Advisors and Blue Rock-AG, an investment management company, and is currently the Chief Financial Officer of PainQX. Mr. Ruckdaeschel currently serves as a member of board of directors for private and Nasdaq-listed companies operating in diverse sectors.

Financial Forecasts The foundational science and early discovery work has been funded by the Jean & George Brumley Jr. Neonatal Perinatal Research Institute, Duke Scholar’s Award, Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) and the National Center for Advancing Translational Sciences (NCATS). Tellus has and will continue to finance operations, drug product development and IND-enabling activities through non-dilutive funding sources, including Duke Clinical & Translational Institute Awards, SBIR, corporate-sponsored research, patient foundations and founder contributions, until the need for venture investment to support clinical studies. Our revenue model involves licensing the lead program upon reaching a value inflection-generating development milestone (e.g., Ph1b/2) after which subsequent development and commercialization will be managed by a biopharmaceutical partner. As the mission of Tellus is to ensure development of treatments for newborns with brain injury, we are prepared to pursue further venture investment following Ph1b/2 completion, company acquisition or an IPO to achieve the company's goals. Also, our product is eligible for a Rare Pediatric Disease Priority Review Voucher which is transferrable and sell for $200M on average.

49

URO-1, Inc. 101 North Chestnut, Suite 101 Winston-Salem, NC 27101 Phone: 336 930-5464 www.uro1medical.com tbelleza@uro1medical.com

Presenter(s)

Ted Belleza, President and CEO Ted has spent over 30 years developing and commercializing endoscopic instruments for General Surgery, Gynecology and Urology. He played pivotal roles in the successful exits of Cooper Lasersonics (Heraeus gmbh), BEI Medical (Boston Scientific), InnerDyne (MEDTRONIC), and SurgRx (Ethicon Endosurgery). In 2010, he co-founded Endosee https://www.endosee.com, which was acquired by CooperSurgical in 2014. He received his Bachelor’s degree from Santa Clara University.

Jack Snoke, Chief Operating and Technology OfficerJack founded inno (Atlanta), a full service design and development consultancy which for 18 years, developed medical devices (Johnson & Johnson, CR Bard, Abbott Labs) and consumer products (Coca-Cola, Sears Craftsman Power Tools, Sunbeam). After selling the company, he continued to develop and license medical (Biomet) and consumer (Weber Grills) products. In his most recent venture Jack developed a steerable endoscope that was licensed to an entity that developed a disposable hysteroscope. Jack received his degree in Industrial Design from Georgia Tech.

Company Profile

URO-1, Inc. (“URO-1”) is a privately held emerging medical device company developing proprietary solutions for office procedures in urogynecology and urology. It was founded as an LLC in August 2016 and became a C Corporation (Delaware) in March 2017. It addresses two of the largest and fastest growing clinical/market opportunities in pelvic health: BOTOX™ Treatment for Overactive Bladder (OAB) and Prostate Cancer Biopsy. Its sole focus in the next 3 years is the US market

The key attributes of the company are:

1. Proven management that has started companies and exited with positive investor returns in the space.

2. Proprietary opportunities in the large and demographically-attractive Gynecology/Urology market with legitimate interest from three strategics one of which the company CEO has successfully completed two prior transactions.

3. Demonstrated remarkable competence in rapid development, including FDA clearance, of initial product under budget and ahead of plan.

The company is in pre-commercialization of its initial product, the Repris™ Bladder Injection System which has been cleared by the FDA. Its short-term goals are to execute a pre-launch tactical plan for Repris and complete development of two other products, ReprisMB™ Bladder Injection System and PneuGen™ Prostate Biopsy System. The company will then execute a concerted market launch of all three products at the American Urological Association meeting, May 2019 Its long-term goal is to achieve market traction for all three products by Q4 2020 and secure market shares of 15-20% for each of its products by 2023

Product and Technology The Repris Bladder Injection System is especially designed to follow a specific protocol for injecting BOTOX™ (Allergan, plc) into the bladder wall to treat overactive bladder OAB) in women. This protocol has been shown to reduce urinary retention, the most common post procedure complication and the single reason for hindering more rapid and broader adoption of the procedure ReprisMB (Microbial Barrier) is a product line extension that addresses the emerging logistical and cost challenges encountered with centralized reprocessing of endoscopes used in office procedures. Such challenges are primarily

encountered in hospital owned physician practices. Both products feature the company’s Re4m memory cannula

platform and Rely self-metering syringe. The Seeclude™ endoscope isolation tip is featured in ReprisMB.

The Re4m memory cannula mimics the features of nitinol (nickel titanium), the memory metal used in medical devices, at a fraction of the cost. The Rely self-metering syringe delivers a precise pre-determined dose per

50

injection site without the physician having to look away from the video monitor and losing his/her target. Both features enable the physician to complete the procedure without assistance. The Seeclude endoscope isolation tip consists of an elastic polymer bonded on the tip of the cystoscope lumen of the Repris introducer to isolate the cystoscope lens from contaminants while preserving visualization of the bladder cavity. This will allow the cystoscope lens to be used in consecutive cases without the time-consuming and costly reprocessing at a central facility. A 510k application will be filed in late Q4 2018 with approval expected in late Q1 to early Q2 2019 when the product will be introduced. The PneuGen™ Prostate Biopsy System replaces the one-at-a-time tissue core sampling and retrieval that is the practice with all current devices. In the setting of multiple (12-18) and saturation (>30) biopsies, this is the single highest contributor to procedure time resulting in unnecessary patient discomfort, increased infection risk and loss of efficiency. The PneuGen System enables multi-core sampling, automatic retrieval, and storage. This increases procedure efficiency and reduces patient discomfort and infection risk. A working prototype will be demonstrated to select Key Opinion Leaders (KOLs) at the Society of Urologic Oncology in November 2018. A 510K application will be filed in mid-December 2018. Approval is expected in late Q1 to early Q2 2019. The product will be introduced in Q2, 2019. 3 formal patent applications have been filed and are in various stages of prosecution. 8 provisional patents have also been filed. A fourth formal patent application will be filed by Nov. 15, 2018.

Market Potential

Since FDA approval in 2013, adoption of BOTOX for OAB has been rapid with an estimated 320,000 US procedures in 2017 growing to 1,000,000 in 2022. However, an even broader and more rapid adoption is hindered because 30-50% of patients refuse treatment or not return for repeat treatments due to concerns over urinary retention. Absent this complication, there would have been 500,000 US procedures in 2017. There were 1,300,000 US prostate biopsy procedures in 2013. These procedures are projected to increase by at least 240,000 every year due to the aging of the population and increasing adoption of active surveillance (AS) in lieu of surgery or radiation therapy for men with equivocal biopsy results

Current needle systems for BOTOX injection are the same ones used since the early 2000s to inject bulking agents into the bladder neck to treat incontinence. The market leader is Laborie, followed by COLOPLAST, COOK, Richard Wolf and Olympus. The primary basis of competition is needle sharpness, not the ability to meet the aforementioned procedure requirements. Prostate biopsy needle systems have not changed in decades. The dominant market leader is C.R. Bard now a part of Becton Dickinson & Co. Other competitors are CareFusion (Becton Dickinson & Co.), Cook, Merit Medical and Argon Medical.

At launch the company will target urogynecologists (Repris & ReprisMB), Centers for Excellence in Prostate Cancer (PneuGen) and large urology group practices, www.lugpa.com (Repris, ReprisMB, PneuGen), deploying direct sales reps in select territories with a critical volume of sales opportunities.

Projected Income Statement

($ in 000) 2019 2020 2021 2022 2023

Total Net Revenue. $ 673 100% $ 7,012 100% $ 22,217 100% $ 37,498 $100% $ 48,806 100%

Cost of Goods Sold 157 23% 1,415 20% 4,493 20% 7.461 20% 9,678 20%

Gross Margin $ 515 77% $ 5,597 80% $ 17,723 80% $ 30,037 80% $ 39,128 80%

Total Operating Exp. 2,345 349% 6,800 97% 13,798 62% 18,872 50% 21,809 45%

EBIT $(1,830) -272% (1,203) -17% 3,925 18%. 11,165. 30% 17,318 35%

Raising $6.0M in Series B to complete development of and commercialize all three products in its pipeline

Cash positive – Q1 2021

51

Vova Ida Therapeutics, LLC (Early Stage) 5500 Military Trail Suite 22 #119 Jupiter, FL 33458 Phone: (561) 454-9564 info@vovaidatherapeutics.com

Presenter Corinne Lasmézas, D.V.M., Ph.D., Chairman & CEO of Vova Ida Therapeutics (VIT), a pharmaceutical company that specializes in the discovery and development of drugs to treat neurodegenerative diseases. C. Lasmézas received her Doctorate of Veterinary Medicine from the University of Toulouse, France, and her Ph.D. in Neurosciences from the University Pierre & Marie Curie, Paris, France.

Company Profile Vova Ida Therapeutics (VIT) is a Florida based start-up company dedicated to the discovery and development of drugs to treat age-related neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. The company originated from innovations made by Dr. Lasmézas at The Scripps Research Institute, Florida. VIT’s short-term objectives are the preclinical development of existing therapeutic leads as well as pipeline expansion. The long-term goal and mission statement of VIT is to turn neurodegenerative diseases into treatable disorders.

Product and Technology Alzheimer’s and Parkinson’s disease patients are being offered drugs that address only some symptoms, providing partial relief without preventing the worsening of brain damage. At the present time, there is no disease-modifying treatment for any age-related neurodegenerative disease. VIT is developing drugs to interfere directly with the cause of age-related neurodegenerative diseases, namely toxic protein aggregates damaging brain cells. VIT uses a proprietary drug discovery method tailored to address this disease mechanism.

Market Potential The number of people affected by neurodegenerative diseases worldwide is estimated to amount more than 40 million individuals. 1 out of 3 seniors dies with dementia. Currently, in the US, 5 million people live with Alzheimer’s disease and 1 million with Parkinson’s disease. Projections show the number of patients tripling by 2050 (www.alz.org). Competitors include pharmaceutical and biotech companies developing disease-modifying treatments using different approaches (e.g. biologics). The market for disease-modifying treatments for age-related neurodegenerative diseases will be a new market.

Management Team Corinne Lasmézas, D.V.M., Ph.D., Chairman & CEO, is the founder of VIT. C. Lasmézas is an expert in neurodegenerative diseases and therapeutic development. She has led research labs in France and in the USA (currently at Scripps Research, Florida), and has been an advisor to several US and European government agencies and pharmaceutical companies. Charles Weissmann, M.D., Ph.D., Head of the Advisory Board, is a renown molecular biologist who discovered the gene of interferon alpha, a major breakthrough for antiviral therapies, and co-founder of Biogen Idec. He is Professor Emeritus from the University of Zurich, Switzerland, and Scripps Research, Florida, USA. Denis Shulyaev, PhD, President. D. Shulyaev has held several VP corporate positions in the field of business development and strategic alliances.

Financial Forecasts VIT is seeking up to $12 million in financing for the preclinical development of its therapeutic leads for Alzheimer’s and Parkinson’s diseases and the expansion of its pipeline. Successful completion of VIT’s 3-year work plan will deliver FDA-approved investigational new drugs for first-in-kind treatments of Alzheimer’s and Parkinson’s diseases. It will open up new opportunities for VIT to partner, generate licensing revenue, extend its therapeutic pipeline and consider exit opportunities.

52

Jeff Arnold – Keynote Chairman and CEO, Sharecare

Jeff Arnold is chairman and CEO of Sharecare, a digital health company he founded with Dr. Mehmet Oz to help people access and manage all of their health resources in one place. Sharecare’s personalized and comprehensive platform connects consumers, employees and health plan members to the knowledge, evidence-based programs and health professionals they need by building each user a unique, dynamic health profile.

Under Jeff's leadership, Sharecare has been recognized as best-in-industry by numerous organizations. For its innovations in digital health, Sharecare has received multiple Stevie® Awards – including a Silver Stevie for Company of the Year in the Health Products and Services and Pharmaceuticals category – as well as multiple honors from The Webby Awards, Appy Awards, Telly Awards and Digital Health Awards. Sharecare also has been named to Deloitte's Technology Fast 500™, the Healthcare Informatics 100, the Association for Corporate Growth's Fast 40, the Technology Association of Georgia's Top 10 Innovative Technology Companies and "Emerging Company of the Year” by the Metro Atlanta Chamber.

Prior to Sharecare, Arnold was chairman and CEO of HowStuffWorks.com, an award-winning online resource used by millions of people each month which he sold to Discovery Communications, where he served as chief digital strategy officer, and chief architect of The Curiosity Project until December 2011.

In 1998, he founded and served as CEO of WebMD, the first healthcare company to harness the power of the Internet to create a destination for consumers, healthcare institutions and physicians to find trustworthy medical information. Before WebMD, Jeff founded Quality Diagnostic Services (QDS), a cardiac arrhythmia monitoring company which was one of the first companies to use the concept of telemedicine over 25 years ago.

Jeff has been widely recognized for his innovative contributions to media and healthcare during his career, both in his home state of Georgia as well as internationally. Recently, he was recognized by the Technology Association of Georgia as the state's "preeminent technology visionary" when they presented him with the 'Icons of the Industry' Award. In 2013, Jeff was inducted into the Technology Hall of Fame of Georgia and also received the prestigious Phoenix Award, which recognizes companies and individuals who embody strength, tenacity and leadership in Georgia's healthcare information technology industry. Bestowed with the Blumenthal Award by Johns Hopkins University in recognition of his exceptional ability to bridge business and technology, Jeff has received numerous other honors from organizations including the World Economic Forum; Ernst & Young, which named him Entrepreneur of the Year, Southeast; and The IndUS Entrepreneurs (TiE), who presented him with a Lifetime Achievement Award. Jeff also was inducted into the Honor Society of Nursing, Sigma Theta Tau International, as an Honorary Member for his superior achievements and contributions to the advancement of nursing and healthcare on both a national and global level.

Currently chairman of Forbes Travel Guide and co-chairman of Endeavor Atlanta, Jeff also has served on numerous boards for public, private and charitable organizations over the years.

53

Alan Bentley Assistant Vice Chancellor, Vanderbilt Center for Technology Transfer and Commercialization

Alan joined Vanderbilt in June of 2011, and is responsible for all aspects of the university’s technology protection and commercialization related to inventions made by all members of the Vanderbilt community. He is active in several licensing professional societies, and serves on a number of corporate and community boards. Alan has been a registered U.S. Patent Agent since 1999, and is a Certified Licensing Professional.

Prior to joining Vanderbilt, Alan served as the Director of Commercialization for Cleveland Clinic Innovations, the organization’s corporate venturing wing, where he was responsible for the organizations licensing operations. Alan came to the Cleveland Clinic from the University of Virginia, where he served as the Associate Director of the University of Virginia Patent Foundation.

Alan received his Masters Degree in nuclear physics from the University of Virginia, and graduated from Carnegie Mellon University in Pittsburgh, Pennsylvania with honors, receiving separate Bachelors Degrees in electrical engineering and physics.

Jed Cohen Managing Director, Leerink

Jed Cohen joined LEERINK Partners as a Managing Director in 2009 to cover the medical technology sector. Jed has over 24 years of Healthcare Investment Banking experience, including 12 years at

Citigroup and three years at UBS prior to joining LEERINK. Jed's transaction experience includes advisory work and financing assignments with clients

across the healthcare industry, with an exclusive focus on "middle market" / emerging growth segments of the medical technology industry since 2000. Jed's passion is aligning with breakthrough medical technology companies that are looking to create new markets or disrupt existing markets. He received a Bachelor of Science in Economics from the University of Pennsylvania's Wharton School.

Bob Creeden Managing Director, UVA LVG Seed Fund & New Ventures

Bob Creeden, Managing Director of the UVA LVG Seed Fund & New Ventures at the UVA Licensing & Ventures Group (LVG) supports the creation of high-quality ventures based on University technologies and leads the day-to-day operations of the $10 million investment fund.

Since joining LVG in September 2016, Creeden has facilitated four strategic investments in companies emerging from the University portfolio, oversaw the Fund’s first exit from TypeZero Technologies, and launched a curriculum course at the Darden School of Business titled ‘Due Diligence in Seed Funds,’ which is now in its third year.

54

In addition to more than 30 years of experience in commercializing new technologies, both as an entrepreneur and investor, Creeden has more than 20 years of experience as an early stage venture capitalist in the Boston area. He served as Vice President of the Massachusetts Technology Development Corporation, an early stage venture firm that funds technology-based companies in Massachusetts, General Partner at Egan-Managed Capital, a $150 million dollar Boston-based venture fund, and in 2005 he established and implemented the Partners Innovation Fund, ($35M) at Partners HealthCare.

Bob holds a BA in Economics from Holy Cross College and an MBA from Suffolk University, and for six years was a faculty member in the Entrepreneurial Leadership Program of the Gordon Institute at Tufts University.

Bob Crutchfield Managing Director, BrightEdge Venture Fund

BrightEdge is the American Cancer Society’s strategic venture philanthropy platform, targeting investments that advance the commercialization of advanced therapies to treat, detect, and prevent all types of cancer.

Prior to the BrightEdge Fund, Bob was a Sr. Partner at Harbert Growth Partners where he led the healthcare practice. His investments that have been realized where he served as a board member or board observer include

Shipt - acquired by Target in 2017, Wellcentive – acquired by Royal Philips in 2016, nContact - acquired by Atricure in 2014 and Novamin - acquired by GSK in 2009.

He also serves on the boards of the Southeastern Medical Device Association, the Southern Capital Forum, the Innovation Depot, the Birmingham Venture Club, the Global Center for Medical Innovation and the True Vine Foundation.

Most recently, he was the Executive Director of Innovate Birmingham, an 18-month initiative in which he led a team to assess, evaluate and recommend to Birmingham’s economic development organizations strategies for accelerating the growth of that market’s technology-based economy. During this time, he also served as an Operating Advisor to Harbert Growth Partners, after stepping down as the Senior Partner and Healthcare Practice Leader in 2017. Prior to Harbert he was Vice President/General Manager of the Pharmacy Services Division at US Oncology, a privately held, vertically integrated cancer care provider network, that sold to McKesson in 2010. Prior to US Oncology, he was a Senior Executive at Cardinal Health where he served as Vice President/General Manager of New Ventures. Prior to Cardinal he was the founder and CEO of Surgical Innovations & Services, Inc. (SIS). Under his leadership, SIS became a leader in the emerging outsource management sector, with over 300 hospitals and surgery centers under contract.

Bob is a graduate of the University of Georgia and holds Bachelor of Science degrees in Political Science and Chemistry.

55

T (Teo) Forcht Dagi, MD CEO, Boston Neurosciences

Teo is the CEO of Boston Neurosciences, a Boston-based clinical stage venture-funded company developing non-invasive intracranial pressure monitoring technologies for neurological disease and glaucoma. He is also a managing partner in Salutramed, an Atlanta-based biomedical consulting firm, and Director of Life Sciences at Anglo-Scientific at the Royal Institution of Great Britain in London, an early stage VC. Prior to joining Boston

Neurosciences, Teo served as a partner in two US venture capital funds, chaired the medical school at Queen’s University Belfast, and taught at the Program in Biomedical Entrepreneurship in the Harvard-MIT Program in Health Sciences and Technology. He trained in neurosurgery at the Massachusetts General Hospital and is credited with the development of cortical stimulation systems for the treatment of epilepsy, intraventricular use of morphine for intractable pain, and other neurosurgical technologies.

Teo has served as a director of numerous public and private boards, and also of institutions such as the the Wharton School, the DuPree School of Management of the Georgia Institute of Technology and the Georgia Neurosurgical Society, which he also chaired. He is Director-elect of the American Association of Neurological Surgeons.

Teo holds an AB from Columbia, MD and MPH from Hopkins, MTS from Harvard, where he was the Joseph P Kennedy, Jr., Fellow, an MBA from Wharton, the DMedSc from Queen’s University Belfast and a DHC from the Technical University of Kaunas. He holds appointments at Queen’s and at Harvard Medical School and teaches at the National Venture Capital Institute. He is widely published and is often invited to address innovation and safety in surgery. He is an editor of Neurosurgery.

Doug Gooding Business Advisor and Technical Specialist, Knowles Intellectual Property Strategies

Doug currently serves as a Business Advisor and Technical Specialist with Knowles Intellectual Property Strategies (KIPS) in Atlanta, Georgia. In this role, Doug participates in strategy development, U.S. and international patent prosecution, licensing, patentability and freedom to operate analysis and transactional due diligence. Doug’s areas of expertise include molecular biology, drug discovery, pre-clinical drug development, licensing,

biotechnology, and early-stage venture capital investing. Doug’s experience as a life sciences investor and entrepreneur provides him with unique insight when assisting clients.

Prior to joining the firm, Doug served as President and CEO of Altiris Therapeutics. Altiris is an early-stage biopharmaceutical company focused on the development of novel small molecule drugs that inhibit the chemokine receptor CXCR4 for use in stem cell mobilization and other indications. Doug accepted the role with Altiris as board member and investor in a predecessor company, Metastatix, Inc., and was responsible for recapitalizing and repositioning the company with support of several of the original investors.

Prior to Altiris, Doug was the co- founder and CEO of Regado Biosciences, which went public, merged with Tobira Therapeutics and was ultimately purchased by Allergan. Under his leadership, the company raised $50M across three venture capital financings and advanced its lead program through three Phase I studies and a Phase 2a study. Doug led the initial investment and company formation activities for

56

Regado while a Principal at the Aurora Funds, an early-stage life sciences venture capital fund. While at Aurora, Doug served on the Board of Directors and led investments in Regado (founding investor), Metabolon (founding investor), Cropsolution, Metastatix, and Tissue Informatics (acquired by Paradigm Genetics).

Prior to joining Aurora, Doug was a Director of Business Development at Paradigm Genetics (acquired by Clinical Data). Doug also spent four years at Incyte Pharmaceuticals (INCY), where he was the manager of the cDNA Library Construction Group. In addition, Doug worked as a Research Associate at Stratagene Cloning Systems in La Jolla, California.

Doug is actively involved in the life sciences community in the Southeast region, including leadership roles with the BioMed Investors Network and Southeast BIO (SEBIO). In connection with both, he is involved in identifying and screening promising life sciences companies seeking angel and venture investment.

Doug received a Bachelor of Arts in Biology, with a minor in Chemistry, from the University of San Diego and a MBA from the Kenan-Flagler Business School at the University of North Carolina in Chapel Hill, NC.

Steven Hall, PhD. General Partner, Lilly Ventures

Steve brings more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations to Lilly Ventures. Prior to joining Lilly Ventures, Steve was Senior Vice President, Research and Development, at Serenex, Inc. where he was also a co-founder. Prior to joining Serenex, Steve was Site Director, Sphinx Labs, Eli Lilly where he oversaw lead generation efforts and was a key member of a small team that developed and executed a strategy to partner Lilly’s expertise in high-

throughput chemistry with three Japanese pharmaceutical companies with an aggregate value of more than $75MM. Steve started his career as a medicinal chemist with the Squibb Institute for Medical Research and held positions of increasing responsibility for multiple projects in cardiovascular disease. Steve is the author of more than 40 papers and 60 patents. He received his B.S. in chemistry from Central Michigan University and his Ph.D. in organic chemistry from Massachusetts Institute of Technology. Steve is a General Partner with Lilly Ventures and currently sits on the boards of Cavion, Esanex, FORMA Therapeutics, Hydra Biosciences, Kymera Therapeutics, Nimbus, and Lysosomal Therapeutics. Steve also serves as the CEO for Esanex.

57

Shawn Hingtgen, PhD. Founder, Falcon Therapeutics

Shawn Hingtgen, Ph.D., is pioneering a new treatment for cancer using induced neural stem cells to deliver therapeutic agents at the UNC Eshelman School of Pharmacy. He is also the founder of Falcon Therapeutics, founded to advance the discoveries generated in the Hingtgen lab towards the clinic to redefine the care for patients with cancers that are currently incurable. The company’s initial successful research was also in glioblastoma, but they have

developed their personalized tumor-homing cell therapy technology into a platform able to treat solid tumor cancers, childhood cancers and metastatic disease. Hingtgen joined the School’s Division of Molecular Pharmaceutics and Pharmacoengineering as an assistant professor in 2012. He holds a joint appointment as an assistant professor in the Department of Neurosurgery at the UNC School of Medicine. In 2014 he received the Young Investigator Award from the Society for Neuro-Oncology and was a finalist for the Damon Runyon-Rachleff Innovation Award from the Damon Runyon Cancer Research Foundation in 2013. He is the author of twenty-five refereed papers and articles with an h-index of 15 cited more than 700 times, as well as two book chapters. Hingtgen completed his undergraduate work and earned his Ph.D. in anatomy and cell biology from the University of Iowa. He then completed postdoctoral fellowships with Ralph Weissleder, M.D., Ph.D., and Khalid Shah, Ph.D., at Harvard Medical School and Massachusetts General Hospital in Boston.

Justin, Klein, MD, JD Partner, NEA

Justin Klein joined NEA in 2006 and is a Partner on the healthcare team. He focuses on medical device, healthcare technology, and biopharmaceutical company investments. He serves as a director of ChromaCode, FIRE1, Intact Vascular, Personal Genome Diagnostics, PhaseBio Pharmaceuticals (NASDAQ: PHAS), Relievant MedSystems, Senseonics (NYSE: SENS), VertiFlex, Vesper Medical, and VytronUS. Justin’s past board memberships and investments include Cartiva (acquired by Wright Medical), CV Ingenuity

(acquired by Covidien), Nevro (NYSE: NVRO), Topera (acquired by Abbott), TriVascular (NASDAQ: TRIV), and Ulthera (acquired by Merz). He is also a member of the advisory boards for the National Venture Capital Association’s Medical Industry Group and its Medical Innovation and Competitiveness Coalition (MedIC), as well as a member of AdvaMed's Business Development Committee.

Prior to NEA, Justin worked for the Duke University Health System—reporting directly to the hospital CEO on health system strategy, finance and clinical service unit operations—as Duke built one of the nation's first and largest healthcare integrated delivery systems. Justin concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School. He has also served as a member of the Board of Trustees of Duke University, where he earned his AB in Economics and his BS in Biological Anthropology and Anatomy.

58

Charles Kunsch, PhD Senior Director, AbbVie Ventures

Chuck has over twenty five years of experience in biopharmaceutical R&D, business development and corporate venture capital investing. Since 2013, Chuck has been a member of AbbVie’s corporate Venture Investment team in Cambridge, MA focusing on early-stage investments in life sciences. Prior to joining the Ventures team, he served as a Director in Abbott’s Global External Research organization where he was responsible for the identification,

assessment, and development of early-stage partnerships across Abbott’s therapeutic areas. Chuck served as Vice President of Discovery at AtheroGenics, Inc leading teams to advance several programs into the clinic and started his career at Human Genome Sciences. Dr. Kunsch obtained his Ph.D. from Penn State’s College of Medicine, is an inventor on more than 30 patents and has authored more than 45 peer-reviewed manuscripts, reviews and book chapters.

Dennis Liotta, PhD Executive Director, Emory Institute for Drug Development

Dennis Liotta, PhD, serves as Executive Director of the Emory Institute for Drug Development and Samuel Candler Dobbs Professor in the Department of Chemistry at Emory University. Dr. Liotta is recognized as one of the premier discoverers of novel therapeutics in the United States, having been the inventor of record for several clinically important antivirals and associated with the invention of ten FDA approved therapeutics.

Dr. Liotta joined Emory in 1976. Since that time, he has authored over 230 research publications and more than 70 issued US patents. Dr. Liotta has also supervised numerous postdoctoral and graduate students and has received several teaching awards, including Emory University’s Thomas Jefferson Award, the highest faculty honor given at Emory. He is a Fellow of both the American Association for the Advancement of Science and the American Chemical Society. Dr. Liotta was elected to the National Academy of Inventors in 2014 and the Medicinal Chemistry Hall of Fame in 2010. Dr. Liotta also is the co-director of the Republic of South Africa Drug Discovery Training Program and a member of the Discovery and Developmental Therapeutics Research Program at Winship. Dr. Liotta earned his PhD in Organic Chemistry from the City University of New York in 1974. Following this, he completed his postdoctoral fellowship at Ohio State University.

59

Linda Lohn, PhD Senior Director, Worldwide R&D, Pfizer

As Senior Director in External Science and Innovation at Pfizer, Linda Lohr leads external partnering efforts for Pfizer across the Southern and Central US. With over 20 years of experience in the pharmaceutical industry, Linda has worked in both small and large corporate environments from early through late stage drug development. She received her Ph.D. in chemistry from Yale, and did her post-doctoral work at Exxon-Mobil. Linda later joined Otsuka

Pharmaceuticals, where she interfaced with scientists across academia, industry, and government and was subsequently recruited to join Pfizer where she’s held roles of increasing responsibility across R&D. In her current role, she established a new external partnering presence for Pfizer in Texas and across the Central and Southern US, and she launched Pfizer’s inaugural “ITEN” collaboration model -- a novel, multi-year external partnership to identify new drug targets spanning multiple therapeutic areas. Linda continues to balance scientific strategy with business drivers to champion external collaborations across the Southern and Central US to support Pfizer’s R&D portfolio. Linda is the author of numerous external scientific publications and presentations and invited book chapters. She has won multiple awards for accelerating drug development and pioneering new technology approaches. In her free time, she is an artist and entrepreneur.

Gladys Nunez Principal, Amgen Ventures

Gladys Nunez joined Amgen in 1997 and currently leads diligence and completion of venture investments. Prior to Amgen Ventures in 2014, Gladys spent over 10 years in Amgen's Technology licensing group prospecting, negotiating and establishing external alliances support for Amgen's R&D organization. Prior to joining business development Gladys worked 7 years in R&D, concurrent between Amgen and AstraZeneca. Gladys holds an MS in

Biochemical Pharmacology from the University of Southhampton in England.

Timothy Patrick President, CEO and Co-Founder of Cartiva

Tim Patrick was President, CEO and co-founder of Cartiva, Inc., which Wright Medical acquired in October 2018. A medical device veteran, Tim has more than 35 years of successful leadership experience in general management and product commercialization. Cartiva received U.S. Premarket Approval in 2016 for the first, cartilage-like

orthopedic implant approved by FDA. Its unique, synthetic polymer mimics the properties of natural cartilage. The initial indication was for great toe osteoarthritis, but products are being developed for other joints, including the hands and knees. From 1996 to 2005, Tim was President and CEO of Proxima Therapeutics, Inc., a medical device company he co-founded. It developed and marketed innovative local radiation delivery systems for treating breast cancer, delivering local radiation therapy following breast-conserving surgery. Proxima was acquired by Cytyc Corporation in 2005.

60

From 1994 to 1996, Tim was President of Gesco International, the leading manufacturer of peripherally inserted central venous catheters, acquired by C.R. Bard. Before that he ran two high growth divisions for McGaw Inc., an infusion equipment and drug delivery company which was acquired by B. Braun. He also held a number of sales and sales management positions at American Hospital Supply Corporation. Tim has served on the Board of Directors of the Advanced Medical Technology Association (AdvaMed), the Board of the Georgia Tech Coulter Grant Committee, and the Board of Georgia Bio. Tim is an inventor on a number of medical device patents, and earned his BA in Zoology from Miami University in Ohio. He has been married to his wife, Debbie, for 36 years and they have 3 adult sons. In his spare time, Tim enjoys fly fishing in different parts of the world.

Owen B. Samuels, MD Medical Director, Emory University Division of Neurointensive Care

Owen B. Samuels MD received his M.D. degree from the State University of New York Health Science Center at Brooklyn and completed his internship and residency training at the University of Rochester Medical Center. He completed a Cerebrovascular Disease Fellowship at Emory University and a second fellowship in Neurologic and Neurosurgical Neurointensive Care Medicine at the University of Pennsylvania.

Dr. Samuels was instrumental in the redevelopment of Emory University Hospital’s Neurointensive Care Unit. In 2007, Emory opened its 20-bed, neurosciences ICU that allows for centralization of the most critical medical services for patients suffering from severe neurologic and neurosurgical brain injury. Emory's new unit is one of the largest and busiest in the country, and one of only a few of this type of unit in the Southeast. It provides an unparalleled level of comfort and convenience, and most importantly, the integration of family members who wish to remain near their loved ones. The Neurosciences Critical Care Unit at Emory University Hospital was selected as the recipient of the 2008 ICU Design Citation Award.

Peter Shagory Executive Vice President, ConMed

Pete joined ConMed Corporation in 2015 and is responsible for corporate strategy and M&A activities for the company. Prior to joining ConMed, Pete spent two years at Cardinal Health where he oversaw the strategic investment and M&A pipeline as well as new business formation efforts for the Medical Products Group within Cardinal Health’s Medical Segment. Prior to joining Cardinal Health, Pete spent fifteen years as a venture capitalist leading the healthcare and life sciences investment effort at Baird Venture Partners in

Chicago for almost ten years, preceded by five years at Vector Fund Management, a life-sciences venture firm also based in Chicago. Prior to his career in venture capital, Pete spent over six years in corporate finance, mergers & acquisitions and merchant banking at JP Morgan & Co. and Banc One Capital Corporation. Pete was the founding Chair of AdvaMed’s National Venture Capital Advisory Board and a founding Board member of the Mid-America Healthcare Investors Network (MHIN). Pete received his undergraduate degree in Business Administration and Finance from Miami University in Oxford, Ohio, and his MBA from the Amos Tuck School at Dartmouth University.

61

Max Wallace, JD Chief Executive Officer, Accelerate Brain Cancer Cure (ABC2)

Max Wallace has served as Chief Executive Officer of ABC2 since August 2008. With his entrepreneurial biotechnology business background, Max is uniquely qualified to lead Accelerate Brain Cancer Cure and its venture philanthropy approach to finding a cure for brain cancer. Prior to ABC2, Max served as Chief Executive Officer of TheraLogics, an anti-

cancer biopharmaceutical company based on technology developed at the University of North Carolina at Chapel Hill. Prior to TheraLogics, he helped found and develop a number of other notable biotech companies, including Trimeris (NASDAQ TRMS), Sphinx Pharmaceuticals Corporation (now part of Eli Lilly & Company), SARCO (now part of PPD/Pharmaco), and Cogent Neuroscience. Max also served as President of the Arbor Group, a consulting firm providing strategic advice to innovation-driven universities, companies and communities. In addition, Max was a member of the Board of Directors of the Emerging Companies Section of the Biotechnology Industry Association (BIO), helped found and served as Chairman of the North Carolina Innovation Foundation and served as a Senior Fellow in Leadership and Innovation at the Institute for Emerging Issues at North Carolina State University, working on issues of public policy related to the development and commercialization of innovative technologies. He was a founding director of Duke University's investment management company and was legal counsel for the Duke Medical Center. Max earned a B.A. from Duke and a J.D. from the University of Florida. Broad transaction experience and a wide network enable Scott to provide assistance to companies when raising capital, forming strategic partnerships and analyzing exit options.

Scott Weiner Partner, Pappas Capital

Prior to joining Pappas Capital in 2006, Scott was an investment manager and research analyst for Silverback Asset Management’s life science fund, where he focused on healthcare securities investing. Before joining Silverback, he spent three years at Chicago Growth Partners focused on healthcare venture investments, and prior to that, he spent three and a half years in investment banking at Lehman Brothers where he worked in New

York, London and Hong Kong.

Scott currently serves as a director for Reneo Pharmaceuticals, and as an observer for 4D Molecular Therapeutics, Envisia Therapeutics, IlluminOss Medical, Liquidia Technologies, Milestone Pharmaceuticals, Thrasos Therapeutics and VelosBio. He previously served as a director for Rotation Medical (acquired by Smith & Nephew), and as an observer for LipoScience (NASDAQ: LPDX) (acquired by LabCorp) and TESARO (NASDAQ: TSRO). Scott is also a board member for the Council for Entrepreneurial Development (CED) and a member of the Investor Advisory Board of the Florida Institute for the Commercialization of Public Research.

62

2018 SEBIO Awards

Over the past two decades, the Southeast has seen an increasing number of startups and venture capital investments. This maturation of the regional startup ecosystem has been spurred by an increase in notable exits and an increased focus and commitment from universities, state legislatures, local government and local financiers. Annually, SEBIO recognizes best in class deals by the region’s biomedical companies in five categories: Public Offering, Strategic Acquisition, Strategic Investment, Venture Funding and Initial Venture Funding. The finalists for this year’s awards are:

Finalists: Public Offering Liquidia Technologies | Durham, NC - Liquidia raised $50 M in its initial public offering, which it will use to advance its innovative, particle-engineering drug delivery products. Adial Pharma | Charlottesville, VA - Adial raised $7.3 M in its initial public offering, which it will use to advance AD04, a therapeutic which can be used in the treatment of alcohol use disorder (AUD). Innovate Biopharmaceuticals | Raleigh, NC - Concurrent with a $21 M raise from current and new investors, Innovate completed its reverse merger with Monster Digital and is now publicly traded (INNT).

Finalists: Strategic Acquisition K2M | Leesburg, VA - K2M develops and manufactures a variety of implants, instruments, and disposables for the treatment of spinal pathologies. This Virginia-based company announced in August its acquisition by Stryker for $1.4 billion.

Cartiva | Atlanta, GA - Cartiva developed a synthetic cartilage implant for treating arthritis at the base of the great toe. Cartiva was acquired this year by Wright Medical for $435 M. Avanos Medical (Formerly Halyard Health) | Alpharetta, GA - Halyard sold its Surgical & Infection Control business to Owens & Minor for $710mm to finance continued growth of its core medical device business, with the company rebranded as Avanos Medical in mid-2018 and remains in Alpharetta.

Finalists: Strategic Investment Lacerta Therapeutics | Gainesville, FL - Lacerta Therapeutics, a clinical stage gene therapy company, has secured $30 M in equity investment from Sarepta Therapeutics.

HedgePath Pharmaceuticals | Richmond, VA - Richmond-based HedgePath Pharmaceuticals secured $1.6 M in funding from Mayne Pharma to advance its SUBA-Itraconazole clinical and regulatory program. Humacyte | Durham, NC - Humacyte secured a $150 M strategic investment from Fresenius Medical, the world’s largest dialysis company, to commercialize the product for dialysis applications.

Finalists: Venture Funding

63

Surterra Wellness | Atlanta, GA - Surterra Wellness, a medical marijuana company, has raised over $65 M in Series C funding this year. Precision Biosciences | Durham, NC - Precision Biosciences’ has secured $110 M in Series B funding to pursue clinical deployment of its immuno-oncology, off-the-shelf CAR-T product. Soluble Systems (now Solsys Medical) | Newport News, VA - Soluble Systems raised $ 19 M in Series E funding to further their wound care product development.

Finalists: Initial Venture Funding Locus Biosciences | Raleigh, NC - Locus Biosciences has raised $19 M in Series A funding to develop its next generation CRISPR-Cas platform for precision antimicrobials. Morphogenesis | Tampa, FL - Morphogenesis has raised $16 M in Series A funding to advance their immune system-based cancer therapy, ImmuneFX.

Stride Bio | Durham, NC - StrideBio has secured $15.7 M in Series A funding to continue development of their gene therapy programs.

64

65

Committed to SuccessKilpatrick Townsend helps established and emerging companies, as well as academic and research institutions and

investors, operating at the convergence of health care delivery, life sciences, and technology. With a unique blend of

experience and expertise across health care, life sciences, and technology fie

l

ds, al ong wi th deep indust ry- speci fic

transactional, intellectual property, and litigation knowledge, the firm hel ps cl ient s navi gat e the chal lenges associ at ed

with innovation and advances in technology.

Our internationally-recognized team provides comprehensive legal and business solutions to consumer product,

biomedical, chemical, and life sciences companies.

We cover:

• Patent counseling, licensing, prosecution, and

enforcement

• Trademark registration and enforcement

• Venture capital and corporate fin

a

nce

• General corporate, M&A, and securities

• Health care, transactional, and litigation services

• Technology transfer and transactions

• Contracts and commercial agreements

www.kilpatricktownsend.com© 2018 Kilpatrick Townsend & Stockton LLP

66

67

68

69

LEARN MORE AT SCRA.ORG/FACILITIES

• Adjacent to MUSC which

has $275 million of

research and proprietary

discoveries

• Partnership & innovation

opportunities to create new

solutions and companies

A facility dedicated to

collaborative,

market-driven Life

Science research

and commercialization.

DISCOVERY DISTRICT

JOIN THE

DISCOVERY

DISTRICT AT

22 WESTEDGE

70

71

72

73

74

Investing in biomedical innovation in the Southeast for over 20 years

Boston Toronto Montreal Vancouver

To get in touch with Lumira, please contact Gerry Brunk, Managing Director, gbrunk@lumira.vc

75

is proud to support the

SEBIO Investor Forum

General Partners

John Crumpler Robert A. Ingram

Kenneth B Lee Douglas Reed, MD

Clay Thorp Christy Shaffer, Ph.D

Hatteras Venture Partners is a venture capital firm based in Durham, NC, with a focus on

healthcare and human medicine. Founded in 2000, our team brings operational experience, a successful track record, and a proven ability to

enhance the value of new biomedical companies. With five funds, the firm has

approximately $450 million under management.

www.hatterasvp.com

76

77

78